TY  - JOUR
AU  - Marinko, Marija
AU  - Novaković, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4980
AB  - Hydrogen sulfide (H2 S) is the youngest member of the gasotransmitters family consisting
of nitric oxide (NO) and carbon monoxide (CO). This signalling molecule is implicated in the
regulation of a wide range of processes, such as inflammation, pain, and tissue repair, and has an
important role in signalling processes affecting cardiovascular health, either as an independent
effector or as an enhancer of the NO system.
With the discovery of the H2 S role in the pathogenesis of many diseases, the development
of new pharmaceuticals that could be useful in conditions with disturbed levels of endogenous
H2 S began. Today, the development of H2 S-releasing drugs has reached the level of clinical
studies. Drugs such as SG1002, aimed at the treatment of heart failure, and ATB-346, aimed at
the treatment of arthritis, have been tested in Phase I/II clinical studies and have shown significant
therapeutic potential. Additionally, it has been shown that some already known drugs, such as
zofenopril, produce part of their beneficial effects by releasing H2 S.
Evidence from clinical studies presented in this paper encourages further clinical testing of
H2 S-based therapeutics and the possibility of their application in a wide range of diseases, such
as hypertension, diabetes and chronic kidney disease.
AB  - Vodonik-sulfid (H2S) je najmlađi član porodice gasovitih medijatora koju čine azot-oksid
(NO) i ugljen-monoksid (CO). Ovaj signalni molekul uključen je u regulaciju širokog spektra
procesa, kao što su zapaljenje, bol, reparacija tkiva, i ima važnu ulogu u signalnim procesima koji
utiču na zdravlje kardiovaskularnog sistema, bilo kao nezavisni efektor ili kao pojačivač NO
signalnog puta.
Sa otkrivanjem uloge H 2 S-a u patogenezi mnogih bolesti, započeo je razvoj novih
farmaceutika koji bi mogli biti od koristi u stanjima sa poremećenim nivoima endogenog H2 S-a.
Razvoj lekova koji oslobađaju H2S danas je dosegao nivo kliničkih studija. Lekovi poput SG1002,
za terapiju srčane insuficijencije, i ATB-346, za terapiju artritisa, ispitivani su u Fazi I/II kliničkih
studija i pokazali značajan terapijski potencijal. Dodatno, pokazano je da neki već poznati lekovi,
poput zofenoprila, deo svojih korisnih efekata ostvaruju upravo oslobađanjem H 2 S-a.
Dokazi iz kliničkih studija izneti u ovom radu ohrabruju dalja klinička testiranja terapeutika
baziranih na H2 S-u i mogućnost njihove primene u širokom spektru bolesti, poput hipertenzije,
dijabetesa i hronične bolesti bubrega.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Hydrogen sulfide-releasing therapeutics - how far have we come in clinical studies?
T1  - Lekovi koji oslobađaju vodonik-sulfid – dokle smo stigli u kliničkim studijama?
VL  - 73
IS  - 3
SP  - 173
EP  - 189
DO  - 10.5937/arhfarm73-44691
ER  - 

@article{
author = "Marinko, Marija and Novaković, Aleksandra",
year = "2023",
abstract = "Hydrogen sulfide (H2 S) is the youngest member of the gasotransmitters family consisting
of nitric oxide (NO) and carbon monoxide (CO). This signalling molecule is implicated in the
regulation of a wide range of processes, such as inflammation, pain, and tissue repair, and has an
important role in signalling processes affecting cardiovascular health, either as an independent
effector or as an enhancer of the NO system.
With the discovery of the H2 S role in the pathogenesis of many diseases, the development
of new pharmaceuticals that could be useful in conditions with disturbed levels of endogenous
H2 S began. Today, the development of H2 S-releasing drugs has reached the level of clinical
studies. Drugs such as SG1002, aimed at the treatment of heart failure, and ATB-346, aimed at
the treatment of arthritis, have been tested in Phase I/II clinical studies and have shown significant
therapeutic potential. Additionally, it has been shown that some already known drugs, such as
zofenopril, produce part of their beneficial effects by releasing H2 S.
Evidence from clinical studies presented in this paper encourages further clinical testing of
H2 S-based therapeutics and the possibility of their application in a wide range of diseases, such
as hypertension, diabetes and chronic kidney disease., Vodonik-sulfid (H2S) je najmlađi član porodice gasovitih medijatora koju čine azot-oksid
(NO) i ugljen-monoksid (CO). Ovaj signalni molekul uključen je u regulaciju širokog spektra
procesa, kao što su zapaljenje, bol, reparacija tkiva, i ima važnu ulogu u signalnim procesima koji
utiču na zdravlje kardiovaskularnog sistema, bilo kao nezavisni efektor ili kao pojačivač NO
signalnog puta.
Sa otkrivanjem uloge H 2 S-a u patogenezi mnogih bolesti, započeo je razvoj novih
farmaceutika koji bi mogli biti od koristi u stanjima sa poremećenim nivoima endogenog H2 S-a.
Razvoj lekova koji oslobađaju H2S danas je dosegao nivo kliničkih studija. Lekovi poput SG1002,
za terapiju srčane insuficijencije, i ATB-346, za terapiju artritisa, ispitivani su u Fazi I/II kliničkih
studija i pokazali značajan terapijski potencijal. Dodatno, pokazano je da neki već poznati lekovi,
poput zofenoprila, deo svojih korisnih efekata ostvaruju upravo oslobađanjem H 2 S-a.
Dokazi iz kliničkih studija izneti u ovom radu ohrabruju dalja klinička testiranja terapeutika
baziranih na H2 S-u i mogućnost njihove primene u širokom spektru bolesti, poput hipertenzije,
dijabetesa i hronične bolesti bubrega.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Hydrogen sulfide-releasing therapeutics - how far have we come in clinical studies?, Lekovi koji oslobađaju vodonik-sulfid – dokle smo stigli u kliničkim studijama?",
volume = "73",
number = "3",
pages = "173-189",
doi = "10.5937/arhfarm73-44691"
}

Marinko, M.,& Novaković, A.. (2023). Hydrogen sulfide-releasing therapeutics - how far have we come in clinical studies?. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(3), 173-189.
https://doi.org/10.5937/arhfarm73-44691

Marinko M, Novaković A. Hydrogen sulfide-releasing therapeutics - how far have we come in clinical studies?. in Arhiv za farmaciju. 2023;73(3):173-189.
doi:10.5937/arhfarm73-44691 .

Marinko, Marija, Novaković, Aleksandra, "Hydrogen sulfide-releasing therapeutics - how far have we come in clinical studies?" in Arhiv za farmaciju, 73, no. 3 (2023):173-189,
https://doi.org/10.5937/arhfarm73-44691 . .

TY  - JOUR
AU  - Stojanović, Ivan
AU  - Okiljević, Bogdan
AU  - Radojičić, Zoran
AU  - Novaković, Aleksandra
AU  - Kaitović, Marko
AU  - Tomić, Slobodan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4279
AB  - Background: Anterior mitral leaflet prolapse repair is a highly effective procedure, but despite excellent operative results still has an inferior long‐term durability when compared to posterior leaflet repair. Methods: We analysed mitral repair durability in 74 consecutive patients operated for anterior leaflet prolapse between 2010 and 2021. Their pre‐ and postoperative clinical, echocardiographic data and repair durability as well, were compared with 74 randomly assigned posterior leaflet prolapse patients who underwent valve repair during the same period. Results: While groups were of similar age, patients with anterior leaflet prolapse had an inferior preoperative status in terms of functional reserve, atrial fibrillation, operative risk, ejection fraction and had more dilated left heart chambers as well. 1, 5, and 10‐year freedom from repair failure was 87.1 ± 4.6%, 79.8 ± 6.5% and 50.7 ± 12.5% in the anterior, and 98.5 ± 1.5% respectively in the posterior leaflet group. Atrial fibrilation (hazard ratio [HR] 5.365; 95%; confidence interval [CI] 1.093–26.324 p = .038) and left ventricle end‐systolic diameter (HR 1.160 95%; CI 1.037–1.299 p = .010) independently predicted anterior leaflet repair failure. Receiver Operating Curve analysis established left ventricle end‐systolic diameter ≤42 mm as a cut‐off value associated with improved anterior leaflet repair durability. Accordingly, 10‐year repair durability in a subset of patients, with preserved left ventricle end‐systolic diameter (≤42 mm) was 86.4 ± 7.8%. Conclusion: Better long‐term repair durability in patients with anterior mitral leaflet prolapse and preserved sinus rhytm and left‐ventricle diameters justifies early reconstructive approach.
PB  - John Wiley and Sons Inc
T2  - Journal of Cardiac Surgery
T1  - Clinical and echocardiographic predictors of the anterior mitral leaflet repair failure
IS  - 37
SP  - 3567
EP  - 3574
DO  - 10.1111/jocs.16945
ER  - 

@article{
author = "Stojanović, Ivan and Okiljević, Bogdan and Radojičić, Zoran and Novaković, Aleksandra and Kaitović, Marko and Tomić, Slobodan",
year = "2022",
abstract = "Background: Anterior mitral leaflet prolapse repair is a highly effective procedure, but despite excellent operative results still has an inferior long‐term durability when compared to posterior leaflet repair. Methods: We analysed mitral repair durability in 74 consecutive patients operated for anterior leaflet prolapse between 2010 and 2021. Their pre‐ and postoperative clinical, echocardiographic data and repair durability as well, were compared with 74 randomly assigned posterior leaflet prolapse patients who underwent valve repair during the same period. Results: While groups were of similar age, patients with anterior leaflet prolapse had an inferior preoperative status in terms of functional reserve, atrial fibrillation, operative risk, ejection fraction and had more dilated left heart chambers as well. 1, 5, and 10‐year freedom from repair failure was 87.1 ± 4.6%, 79.8 ± 6.5% and 50.7 ± 12.5% in the anterior, and 98.5 ± 1.5% respectively in the posterior leaflet group. Atrial fibrilation (hazard ratio [HR] 5.365; 95%; confidence interval [CI] 1.093–26.324 p = .038) and left ventricle end‐systolic diameter (HR 1.160 95%; CI 1.037–1.299 p = .010) independently predicted anterior leaflet repair failure. Receiver Operating Curve analysis established left ventricle end‐systolic diameter ≤42 mm as a cut‐off value associated with improved anterior leaflet repair durability. Accordingly, 10‐year repair durability in a subset of patients, with preserved left ventricle end‐systolic diameter (≤42 mm) was 86.4 ± 7.8%. Conclusion: Better long‐term repair durability in patients with anterior mitral leaflet prolapse and preserved sinus rhytm and left‐ventricle diameters justifies early reconstructive approach.",
publisher = "John Wiley and Sons Inc",
journal = "Journal of Cardiac Surgery",
title = "Clinical and echocardiographic predictors of the anterior mitral leaflet repair failure",
number = "37",
pages = "3567-3574",
doi = "10.1111/jocs.16945"
}

Stojanović, I., Okiljević, B., Radojičić, Z., Novaković, A., Kaitović, M.,& Tomić, S.. (2022). Clinical and echocardiographic predictors of the anterior mitral leaflet repair failure. in Journal of Cardiac Surgery
John Wiley and Sons Inc.(37), 3567-3574.
https://doi.org/10.1111/jocs.16945

Stojanović I, Okiljević B, Radojičić Z, Novaković A, Kaitović M, Tomić S. Clinical and echocardiographic predictors of the anterior mitral leaflet repair failure. in Journal of Cardiac Surgery. 2022;(37):3567-3574.
doi:10.1111/jocs.16945 .

Stojanović, Ivan, Okiljević, Bogdan, Radojičić, Zoran, Novaković, Aleksandra, Kaitović, Marko, Tomić, Slobodan, "Clinical and echocardiographic predictors of the anterior mitral leaflet repair failure" in Journal of Cardiac Surgery, no. 37 (2022):3567-3574,
https://doi.org/10.1111/jocs.16945 . .

TY  - CONF
AU  - Marinko, Marija
AU  - Janković, Goran
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
AU  - Novaković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4492
AB  - Findings from epidemiological studies indicate that polyphenols, widespread in
human diet and with numerous biological activities, act cardioprotectively. Procyanidins are
subclass of polyphenols with high content in commonly consumed foods and beverages, such
as grapes, tea, chocolate, nuts and apples. Cardioprotective abilities of procyanidins, might, at
least partly, attribute to their vasodilator properties. Since exact mechanisms of procyanidin
B2-induced vasorelaxation are unknown, our study aimed to investigate relaxant effect of
procyanidin B2 on isolated human saphenous vein (HSV) and its underlying mechanisms.
Discarded segments of HSV were collected from patients undergoing bypass surgery and
studied in organ baths. Procyanidin B2 caused concentration-dependent relaxation of HSV
precontracted by phenylephrine. The relaxation was strongly affected by inhibitors of
NO/cGMP pathway, L-NAME, hydroxocobalamin and ODQ. Indomethacin, a cyclooxygenase
inhibitor, significantly reduced only relaxation produced by the highest concentrations of
procyanidin B2. Combination of apamin and TRAM-34, selective blockers of small- and
intermediate-conductance Ca 2+ -activated K+ (KCa ) channels (SKCa and IK Ca ), in the presence of
L-NAME and indomethacin, did not additionally affect procyanidin B2-induced relaxation.
Additionally, relaxation induced by procyanidin B2 was partially attenuated by 4-
aminopyridine, predominant blocker of voltage-gated K+ (KV) channels, significantly
inhibited by glibenclamide, selective ATP-sensitive K+ (KATP) channels inhibitor, and almost
abolished by iberiotoxin, highly selective blocker of large-conductance KCa (BKCa ). Our results
revealed that procyanidin B2 acts as a potent vasodilator on isolated human venous graft.
Mechanism of this relaxation of HSV probably involves stimulation of NO production, as well
K+ channels opening, especially BK Ca , and partially KATP and KV
AB  - Nalazi epidemioloških studija ukazuju da polifenoli, široko rasprostranjeni u ljudskoj
ishrani i sa brojnim biološkim aktivnostima, deluju kardioprotektivno. Procijanidini su
podklasa polifenola sa visokim sadržajem u često konzumiranoj hrani i pićima, kao što su
grožđe, čaj, čokolada, orašasti plodovi i jabuke. Kardioprotektivno delovanje procijanidina
može se, bar delimično, pripisati njihovim vazodilatatornim svojstvima. S obzirom da tačni
mehanizmi pomoću kojih procijanidin B2 izaziva vazorelaksaciju nisu poznati, cilj naše
studije bio je da istražimo relaksantni efekat procijanidina B2 na izolovanoj humanoj veni
safeni (HSV) i njegove osnovne mehanizme.Neiskorišćeni segmenti HSV su uzimani od
pacijenata u toku bajpas operacija i ispitivani u kupatilu za izolovane organe. Procijanidin B2
izazvao je koncentracijski-zavisnu relaksaciju HSV prekontrahovane fenilefrinom. Na
relaksaciju su snažno uticali inhibitori NO/cGMP puta, L-NAME, hidroksokobalamin i ODQ.
Indometacin, inhibitor ciklooksigenaze, značajno je umanjio samo relaksaciju izazivanu
najvećim koncentracijama procijanidina B2. Kombinacija apamina i TRAM-34, selektivnih
blokatora Ca 2+ -zavisnih K+ (KCa ) kanala male i srednje provodljivosti (SKCa i IK Ca ), u prisustvu
L-NAME i indometacina, nije dodatno uticala na relaksaciju uzrokovanu procijanidinom B2.
Osim toga, procijanidinom B2 izazvana relaksacija bila je delimično umanjena 4-
aminopiridinom, dominantnim blokatorom voltažno-zavisnih K+ (KV) kanala, značajno
inhibirana glibenklamidom, selektivnim inhibitorom ATP-zavisnih K+ (KATP) kanala, i skoro
potpuno blokirana iberiotoksinom, selektivnim blokatorom K Ca velike provodljivosti (BK Ca).
Naši rezultati pokazuju da procijanidin B2 deluje kao moćni vazodilatator na izolovanom
humanom venskom graftu. Mehanizam ove relaksacije HSV verovatno uključuje stimulaciju
proizvodnje NO, kao i otvaranje K+ kanala, posebno BK Ca , i delimično KATP i KV
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Mechanism underlying vasorelaxation of human saphenous vein induced by procyanidin B2
T1  - Mehanizam vazorelaksacije humane vene safene izazvane procijanidinom B2
VL  - 72
IS  - 4 suplement
SP  - S190
EP  - S191
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4492
ER  - 

@conference{
author = "Marinko, Marija and Janković, Goran and Milojević, Predrag and Stojanović, Ivan and Nenezić, Dragoslav and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei and Novaković, Aleksandra",
year = "2022",
abstract = "Findings from epidemiological studies indicate that polyphenols, widespread in
human diet and with numerous biological activities, act cardioprotectively. Procyanidins are
subclass of polyphenols with high content in commonly consumed foods and beverages, such
as grapes, tea, chocolate, nuts and apples. Cardioprotective abilities of procyanidins, might, at
least partly, attribute to their vasodilator properties. Since exact mechanisms of procyanidin
B2-induced vasorelaxation are unknown, our study aimed to investigate relaxant effect of
procyanidin B2 on isolated human saphenous vein (HSV) and its underlying mechanisms.
Discarded segments of HSV were collected from patients undergoing bypass surgery and
studied in organ baths. Procyanidin B2 caused concentration-dependent relaxation of HSV
precontracted by phenylephrine. The relaxation was strongly affected by inhibitors of
NO/cGMP pathway, L-NAME, hydroxocobalamin and ODQ. Indomethacin, a cyclooxygenase
inhibitor, significantly reduced only relaxation produced by the highest concentrations of
procyanidin B2. Combination of apamin and TRAM-34, selective blockers of small- and
intermediate-conductance Ca 2+ -activated K+ (KCa ) channels (SKCa and IK Ca ), in the presence of
L-NAME and indomethacin, did not additionally affect procyanidin B2-induced relaxation.
Additionally, relaxation induced by procyanidin B2 was partially attenuated by 4-
aminopyridine, predominant blocker of voltage-gated K+ (KV) channels, significantly
inhibited by glibenclamide, selective ATP-sensitive K+ (KATP) channels inhibitor, and almost
abolished by iberiotoxin, highly selective blocker of large-conductance KCa (BKCa ). Our results
revealed that procyanidin B2 acts as a potent vasodilator on isolated human venous graft.
Mechanism of this relaxation of HSV probably involves stimulation of NO production, as well
K+ channels opening, especially BK Ca , and partially KATP and KV, Nalazi epidemioloških studija ukazuju da polifenoli, široko rasprostranjeni u ljudskoj
ishrani i sa brojnim biološkim aktivnostima, deluju kardioprotektivno. Procijanidini su
podklasa polifenola sa visokim sadržajem u često konzumiranoj hrani i pićima, kao što su
grožđe, čaj, čokolada, orašasti plodovi i jabuke. Kardioprotektivno delovanje procijanidina
može se, bar delimično, pripisati njihovim vazodilatatornim svojstvima. S obzirom da tačni
mehanizmi pomoću kojih procijanidin B2 izaziva vazorelaksaciju nisu poznati, cilj naše
studije bio je da istražimo relaksantni efekat procijanidina B2 na izolovanoj humanoj veni
safeni (HSV) i njegove osnovne mehanizme.Neiskorišćeni segmenti HSV su uzimani od
pacijenata u toku bajpas operacija i ispitivani u kupatilu za izolovane organe. Procijanidin B2
izazvao je koncentracijski-zavisnu relaksaciju HSV prekontrahovane fenilefrinom. Na
relaksaciju su snažno uticali inhibitori NO/cGMP puta, L-NAME, hidroksokobalamin i ODQ.
Indometacin, inhibitor ciklooksigenaze, značajno je umanjio samo relaksaciju izazivanu
najvećim koncentracijama procijanidina B2. Kombinacija apamina i TRAM-34, selektivnih
blokatora Ca 2+ -zavisnih K+ (KCa ) kanala male i srednje provodljivosti (SKCa i IK Ca ), u prisustvu
L-NAME i indometacina, nije dodatno uticala na relaksaciju uzrokovanu procijanidinom B2.
Osim toga, procijanidinom B2 izazvana relaksacija bila je delimično umanjena 4-
aminopiridinom, dominantnim blokatorom voltažno-zavisnih K+ (KV) kanala, značajno
inhibirana glibenklamidom, selektivnim inhibitorom ATP-zavisnih K+ (KATP) kanala, i skoro
potpuno blokirana iberiotoksinom, selektivnim blokatorom K Ca velike provodljivosti (BK Ca).
Naši rezultati pokazuju da procijanidin B2 deluje kao moćni vazodilatator na izolovanom
humanom venskom graftu. Mehanizam ove relaksacije HSV verovatno uključuje stimulaciju
proizvodnje NO, kao i otvaranje K+ kanala, posebno BK Ca , i delimično KATP i KV",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Mechanism underlying vasorelaxation of human saphenous vein induced by procyanidin B2, Mehanizam vazorelaksacije humane vene safene izazvane procijanidinom B2",
volume = "72",
number = "4 suplement",
pages = "S190-S191",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4492"
}

Marinko, M., Janković, G., Milojević, P., Stojanović, I., Nenezić, D., Kanjuh, V., Yang, Q., He, G.,& Novaković, A.. (2022). Mechanism underlying vasorelaxation of human saphenous vein induced by procyanidin B2. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S190-S191.
https://hdl.handle.net/21.15107/rcub_farfar_4492

Marinko M, Janković G, Milojević P, Stojanović I, Nenezić D, Kanjuh V, Yang Q, He G, Novaković A. Mechanism underlying vasorelaxation of human saphenous vein induced by procyanidin B2. in Arhiv za farmaciju. 2022;72(4 suplement):S190-S191.
https://hdl.handle.net/21.15107/rcub_farfar_4492 .

Marinko, Marija, Janković, Goran, Milojević, Predrag, Stojanović, Ivan, Nenezić, Dragoslav, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, Novaković, Aleksandra, "Mechanism underlying vasorelaxation of human saphenous vein induced by procyanidin B2" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S190-S191,
https://hdl.handle.net/21.15107/rcub_farfar_4492 .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Novaković, A.
AU  - Janković, G.
AU  - Stojanović, I.
AU  - Milojević, P.
AU  - Nenezić, D.
AU  - Kanjuh, V.
AU  - Yang, Q.
AU  - He, G.
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4344
PB  - Springer
C3  - European Journal of Clinical Pharmacology
T1  - Relaxation of venous bypass graft induced by procyanidin B2
VL  - 78
IS  - Suppl 1
SP  - S39
EP  - S40
DO  - 10.1007/s00228-022-03333-y
ER  - 

@conference{
author = "Novaković, Aleksandra and Novaković, A. and Janković, G. and Stojanović, I. and Milojević, P. and Nenezić, D. and Kanjuh, V. and Yang, Q. and He, G.",
year = "2022",
publisher = "Springer",
journal = "European Journal of Clinical Pharmacology",
title = "Relaxation of venous bypass graft induced by procyanidin B2",
volume = "78",
number = "Suppl 1",
pages = "S39-S40",
doi = "10.1007/s00228-022-03333-y"
}

Novaković, A., Novaković, A., Janković, G., Stojanović, I., Milojević, P., Nenezić, D., Kanjuh, V., Yang, Q.,& He, G.. (2022). Relaxation of venous bypass graft induced by procyanidin B2. in European Journal of Clinical Pharmacology
Springer., 78(Suppl 1), S39-S40.
https://doi.org/10.1007/s00228-022-03333-y

Novaković A, Novaković A, Janković G, Stojanović I, Milojević P, Nenezić D, Kanjuh V, Yang Q, He G. Relaxation of venous bypass graft induced by procyanidin B2. in European Journal of Clinical Pharmacology. 2022;78(Suppl 1):S39-S40.
doi:10.1007/s00228-022-03333-y .

Novaković, Aleksandra, Novaković, A., Janković, G., Stojanović, I., Milojević, P., Nenezić, D., Kanjuh, V., Yang, Q., He, G., "Relaxation of venous bypass graft induced by procyanidin B2" in European Journal of Clinical Pharmacology, 78, no. Suppl 1 (2022):S39-S40,
https://doi.org/10.1007/s00228-022-03333-y . .

TY  - JOUR
AU  - Marinko, Marija
AU  - Hou, Hai-Tao
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
AU  - Novaković, Aleksandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3901
AB  - Hydrogen sulfide (H2S) represents the third and the youngest member of the gaseous transmitters family. The dominant effect of H2S on isolated vessels is vasodilation. As the mechanism of H2S-induced relaxation in human vessels remains unclear, the present study aimed to investigate the effects of H2S donor, sodium hydrosulfide (NaHS), on isolated human saphenous vein (HSV) and to determine the mechanism of action. Our results showed that NaHS (1 µM–3 mM) induced a concentration-dependent relaxation of endothelium-intact HSV rings pre-contracted by phenylephrine. Pre-treatment with L-NAME, ODQ and KT5823 significantly inhibited NaHS-induced relaxation, while indomethacin induced partial inhibition. Among K+ channel blockers, the combination of apamin and TRAM-34 significantly affected the relaxation produced by NaHS, while iberiotoxin and glibenclamide only reduced maximal relaxation of HSV. NaHS partially relaxed endothelium-intact rings pre-contracted by high K+, as well as phenylephrine-contracted rings in the presence of nifedipine. Additionally, the incubation of HSV rings with NaHS increased NO production. These results demonstrate that NaHS produces the concentration- and endothelium-dependent relaxation of isolated HSV. Vasorelaxation to NaHS probably involves activation of NO/cGMP/PKG pathway and partially prostacyclin. In addition, different K+ channels subtypes, especially SKCa and IKCa, as well as BKCa and KATP channels in high concentrations of NaHS, probably participate in the NaHS-induced vasorelaxation.
PB  - Blackwell Publishing Ltd
T2  - Fundamental and Clinical Pharmacology
T1  - Mechanisms underlying the vasorelaxant effect of hydrogen sulfide on human saphenous vein
VL  - 35
IS  - 5
SP  - 906
EP  - 918
DO  - 10.1111/fcp.12658
ER  - 

@article{
author = "Marinko, Marija and Hou, Hai-Tao and Stojanović, Ivan and Milojević, Predrag and Nenezić, Dragoslav and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei and Novaković, Aleksandra",
year = "2021",
abstract = "Hydrogen sulfide (H2S) represents the third and the youngest member of the gaseous transmitters family. The dominant effect of H2S on isolated vessels is vasodilation. As the mechanism of H2S-induced relaxation in human vessels remains unclear, the present study aimed to investigate the effects of H2S donor, sodium hydrosulfide (NaHS), on isolated human saphenous vein (HSV) and to determine the mechanism of action. Our results showed that NaHS (1 µM–3 mM) induced a concentration-dependent relaxation of endothelium-intact HSV rings pre-contracted by phenylephrine. Pre-treatment with L-NAME, ODQ and KT5823 significantly inhibited NaHS-induced relaxation, while indomethacin induced partial inhibition. Among K+ channel blockers, the combination of apamin and TRAM-34 significantly affected the relaxation produced by NaHS, while iberiotoxin and glibenclamide only reduced maximal relaxation of HSV. NaHS partially relaxed endothelium-intact rings pre-contracted by high K+, as well as phenylephrine-contracted rings in the presence of nifedipine. Additionally, the incubation of HSV rings with NaHS increased NO production. These results demonstrate that NaHS produces the concentration- and endothelium-dependent relaxation of isolated HSV. Vasorelaxation to NaHS probably involves activation of NO/cGMP/PKG pathway and partially prostacyclin. In addition, different K+ channels subtypes, especially SKCa and IKCa, as well as BKCa and KATP channels in high concentrations of NaHS, probably participate in the NaHS-induced vasorelaxation.",
publisher = "Blackwell Publishing Ltd",
journal = "Fundamental and Clinical Pharmacology",
title = "Mechanisms underlying the vasorelaxant effect of hydrogen sulfide on human saphenous vein",
volume = "35",
number = "5",
pages = "906-918",
doi = "10.1111/fcp.12658"
}

Marinko, M., Hou, H., Stojanović, I., Milojević, P., Nenezić, D., Kanjuh, V., Yang, Q., He, G.,& Novaković, A.. (2021). Mechanisms underlying the vasorelaxant effect of hydrogen sulfide on human saphenous vein. in Fundamental and Clinical Pharmacology
Blackwell Publishing Ltd., 35(5), 906-918.
https://doi.org/10.1111/fcp.12658

Marinko M, Hou H, Stojanović I, Milojević P, Nenezić D, Kanjuh V, Yang Q, He G, Novaković A. Mechanisms underlying the vasorelaxant effect of hydrogen sulfide on human saphenous vein. in Fundamental and Clinical Pharmacology. 2021;35(5):906-918.
doi:10.1111/fcp.12658 .

Marinko, Marija, Hou, Hai-Tao, Stojanović, Ivan, Milojević, Predrag, Nenezić, Dragoslav, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, Novaković, Aleksandra, "Mechanisms underlying the vasorelaxant effect of hydrogen sulfide on human saphenous vein" in Fundamental and Clinical Pharmacology, 35, no. 5 (2021):906-918,
https://doi.org/10.1111/fcp.12658 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3260
PB  - Springer
C3  - European Journal of Clinical Pharmacology
T1  - Vasorelaxation of human saphenous vein induced by epicatechin
VL  - 75, Suppl. 1
SP  - S24
EP  - S24
DO  - 10.1007/s00228-019-02685-2
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Nenezić, Dragoslav and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2019",
publisher = "Springer",
journal = "European Journal of Clinical Pharmacology",
title = "Vasorelaxation of human saphenous vein induced by epicatechin",
volume = "75, Suppl. 1",
pages = "S24-S24",
doi = "10.1007/s00228-019-02685-2"
}

Novaković, A., Marinko, M., Janković, G., Stojanović, I., Milojević, P., Nenezić, D., Kanjuh, V., Yang, Q.,& He, G.. (2019). Vasorelaxation of human saphenous vein induced by epicatechin. in European Journal of Clinical Pharmacology
Springer., 75, Suppl. 1, S24-S24.
https://doi.org/10.1007/s00228-019-02685-2

Novaković A, Marinko M, Janković G, Stojanović I, Milojević P, Nenezić D, Kanjuh V, Yang Q, He G. Vasorelaxation of human saphenous vein induced by epicatechin. in European Journal of Clinical Pharmacology. 2019;75, Suppl. 1:S24-S24.
doi:10.1007/s00228-019-02685-2 .

Novaković, Aleksandra, Marinko, Marija, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Nenezić, Dragoslav, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Vasorelaxation of human saphenous vein induced by epicatechin" in European Journal of Clinical Pharmacology, 75, Suppl. 1 (2019):S24-S24,
https://doi.org/10.1007/s00228-019-02685-2 . .

TY  - JOUR
AU  - Janković, Goran
AU  - Marinko, Marija
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
AU  - Novaković, Aleksandra
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3515
AB  - Cardioprotective abilities of procyanidins, might, at least in part, attribute to their vasodilator properties. The present study was undertaken to assess the vasorelaxant effect of procyanidin B2 on isolated human saphenous vein (HSV) and its underlying mechanisms. Procyanidin B2 relaxed phenylephrine-induced contraction of HSV rings in concentration-dependent manner. The relaxation was dependent on the presence of endothelium and was strongly affected by l-NAME, hydroxocobalamin or ODQ, the inhibitors of NO/cGMP pathway. Indomethacin significantly affected only the relaxation produced by the highest concentrations of procyanidin B2. Apamin and TRAM-34 combination, in the presence of l-NAME and indomethacin, did not additionally decreased procyanidin B2-induced relaxation. In the presence of K+ channel blockers, relaxation induced by procyanidin B2 was partially attenuated by 4-aminopyridine, significantly inhibited by glibenclamide and almost abolished by iberiotoxin. Procyanidin B2 also relaxed the contractions induced by phenylephrine or caffeine in Ca2+-free solution. Finally, nifedipine slightly, while thapsigargin strongly antagonized HSV relaxation. Our results indicate that procyanidin B2 induces endothelium-dependent relaxation of HSV, which results primarily from stimulation of NO production, as well K+ channels opening, especially BKCa, and partially KATP and KV. Regulation of the intracellular Ca2+ release and inhibition of Ca2+ influx probably contr
PB  - Elsevier B.V.
T2  - Journal of Pharmacological Sciences
T1  - Mechanisms of endothelium-dependent vasorelaxation induced by procyanidin B2 in venous bypass graft
VL  - 142
IS  - 3
SP  - 101
EP  - 108
DO  - 10.1016/j.jphs.2019.11.006
ER  - 

@article{
author = "Janković, Goran and Marinko, Marija and Milojević, Predrag and Stojanović, Ivan and Nenezić, Dragoslav and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei and Novaković, Aleksandra",
year = "2019",
abstract = "Cardioprotective abilities of procyanidins, might, at least in part, attribute to their vasodilator properties. The present study was undertaken to assess the vasorelaxant effect of procyanidin B2 on isolated human saphenous vein (HSV) and its underlying mechanisms. Procyanidin B2 relaxed phenylephrine-induced contraction of HSV rings in concentration-dependent manner. The relaxation was dependent on the presence of endothelium and was strongly affected by l-NAME, hydroxocobalamin or ODQ, the inhibitors of NO/cGMP pathway. Indomethacin significantly affected only the relaxation produced by the highest concentrations of procyanidin B2. Apamin and TRAM-34 combination, in the presence of l-NAME and indomethacin, did not additionally decreased procyanidin B2-induced relaxation. In the presence of K+ channel blockers, relaxation induced by procyanidin B2 was partially attenuated by 4-aminopyridine, significantly inhibited by glibenclamide and almost abolished by iberiotoxin. Procyanidin B2 also relaxed the contractions induced by phenylephrine or caffeine in Ca2+-free solution. Finally, nifedipine slightly, while thapsigargin strongly antagonized HSV relaxation. Our results indicate that procyanidin B2 induces endothelium-dependent relaxation of HSV, which results primarily from stimulation of NO production, as well K+ channels opening, especially BKCa, and partially KATP and KV. Regulation of the intracellular Ca2+ release and inhibition of Ca2+ influx probably contr",
publisher = "Elsevier B.V.",
journal = "Journal of Pharmacological Sciences",
title = "Mechanisms of endothelium-dependent vasorelaxation induced by procyanidin B2 in venous bypass graft",
volume = "142",
number = "3",
pages = "101-108",
doi = "10.1016/j.jphs.2019.11.006"
}

Janković, G., Marinko, M., Milojević, P., Stojanović, I., Nenezić, D., Kanjuh, V., Yang, Q., He, G.,& Novaković, A.. (2019). Mechanisms of endothelium-dependent vasorelaxation induced by procyanidin B2 in venous bypass graft. in Journal of Pharmacological Sciences
Elsevier B.V.., 142(3), 101-108.
https://doi.org/10.1016/j.jphs.2019.11.006

Janković G, Marinko M, Milojević P, Stojanović I, Nenezić D, Kanjuh V, Yang Q, He G, Novaković A. Mechanisms of endothelium-dependent vasorelaxation induced by procyanidin B2 in venous bypass graft. in Journal of Pharmacological Sciences. 2019;142(3):101-108.
doi:10.1016/j.jphs.2019.11.006 .

Janković, Goran, Marinko, Marija, Milojević, Predrag, Stojanović, Ivan, Nenezić, Dragoslav, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, Novaković, Aleksandra, "Mechanisms of endothelium-dependent vasorelaxation induced by procyanidin B2 in venous bypass graft" in Journal of Pharmacological Sciences, 142, no. 3 (2019):101-108,
https://doi.org/10.1016/j.jphs.2019.11.006 . .

TY  - JOUR
AU  - Sun, Wen-Tao
AU  - Wang, Xiang-Chong
AU  - Novaković, Aleksandra
AU  - Wang, Jun
AU  - He, Guo-Wei
AU  - Yang, Qin
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3361
AB  - Objectives: We recently reported the involvement of ER stress-mediated BKCa channel inhibition in homocysteine-induced coronary dilator dysfunction. In another study, we demonstrated that tetramethylpyrazine (TMP), an active ingredient of the Chinese herb Chuanxiong, possesses potent anti-ER stress capacity. The present study investigated whether TMP protects BKCa channels from homocysteine-induced inhibition and whether suppression of ER stress is a mechanism contributing to the protection. Furthermore, we explored the signaling transduction involved in TMP-conferred protection on BKCa channels. Methods: BKCa channel-mediated relaxation was studied in porcine small coronary arteries. Expressions of BKCa channel subunits, ER stress molecules, and E3 ubiquitin ligases, as well as BKCa ubiquitination were determined in porcine coronary arterial smooth muscle cells (PCASMCs). Whole-cell BKCa currents were recorded. Results: Exposure of PCASMCs to homocysteine or the chemical ER stressor tunicamycin increased the expression of ER stress molecules, which was significantly inhibited by TMP. Suppression of ER stress by TMP preserved the BKCa beta 1 protein level and restored the BKCa current in PCASMCs, concomitant with an improved BKCa mediated dilatation in coronary arteries. TMP attenuated homocysteine-induced BKCa beta 1 protein ubiquitination, in which inhibition of ER stress-mediated FoxO3a activation and FoxO3a-dependent atrogin-1 and Murf-1 was involved. Conclusions: Reversal of BKCa channel inhibition via suppressing ER stress-mediated loss of beta 1 subunits contributes to the protective effect of TMP against homocysteine on coronary dilator function. Inhibition of FoxO3a-dependent ubiquitin ligases is involved in TMP-conferred normalization of BKCa beta 1 protein level. These results provide new mechanistic insights into the cardiovascular benefits of TMP.
PB  - Elsevier Science Inc, New York
T2  - Vibrational Spectroscopy
T1  - Protection of dilator function of coronary arteries from homocysteine by tetramethylpyrazine: Role of ER stress in modulation of BKCa channels
VL  - 113
SP  - 27
EP  - 37
DO  - 10.1016/j.vph.2018.10.009
ER  - 

@article{
author = "Sun, Wen-Tao and Wang, Xiang-Chong and Novaković, Aleksandra and Wang, Jun and He, Guo-Wei and Yang, Qin",
year = "2019",
abstract = "Objectives: We recently reported the involvement of ER stress-mediated BKCa channel inhibition in homocysteine-induced coronary dilator dysfunction. In another study, we demonstrated that tetramethylpyrazine (TMP), an active ingredient of the Chinese herb Chuanxiong, possesses potent anti-ER stress capacity. The present study investigated whether TMP protects BKCa channels from homocysteine-induced inhibition and whether suppression of ER stress is a mechanism contributing to the protection. Furthermore, we explored the signaling transduction involved in TMP-conferred protection on BKCa channels. Methods: BKCa channel-mediated relaxation was studied in porcine small coronary arteries. Expressions of BKCa channel subunits, ER stress molecules, and E3 ubiquitin ligases, as well as BKCa ubiquitination were determined in porcine coronary arterial smooth muscle cells (PCASMCs). Whole-cell BKCa currents were recorded. Results: Exposure of PCASMCs to homocysteine or the chemical ER stressor tunicamycin increased the expression of ER stress molecules, which was significantly inhibited by TMP. Suppression of ER stress by TMP preserved the BKCa beta 1 protein level and restored the BKCa current in PCASMCs, concomitant with an improved BKCa mediated dilatation in coronary arteries. TMP attenuated homocysteine-induced BKCa beta 1 protein ubiquitination, in which inhibition of ER stress-mediated FoxO3a activation and FoxO3a-dependent atrogin-1 and Murf-1 was involved. Conclusions: Reversal of BKCa channel inhibition via suppressing ER stress-mediated loss of beta 1 subunits contributes to the protective effect of TMP against homocysteine on coronary dilator function. Inhibition of FoxO3a-dependent ubiquitin ligases is involved in TMP-conferred normalization of BKCa beta 1 protein level. These results provide new mechanistic insights into the cardiovascular benefits of TMP.",
publisher = "Elsevier Science Inc, New York",
journal = "Vibrational Spectroscopy",
title = "Protection of dilator function of coronary arteries from homocysteine by tetramethylpyrazine: Role of ER stress in modulation of BKCa channels",
volume = "113",
pages = "27-37",
doi = "10.1016/j.vph.2018.10.009"
}

Sun, W., Wang, X., Novaković, A., Wang, J., He, G.,& Yang, Q.. (2019). Protection of dilator function of coronary arteries from homocysteine by tetramethylpyrazine: Role of ER stress in modulation of BKCa channels. in Vibrational Spectroscopy
Elsevier Science Inc, New York., 113, 27-37.
https://doi.org/10.1016/j.vph.2018.10.009

Sun W, Wang X, Novaković A, Wang J, He G, Yang Q. Protection of dilator function of coronary arteries from homocysteine by tetramethylpyrazine: Role of ER stress in modulation of BKCa channels. in Vibrational Spectroscopy. 2019;113:27-37.
doi:10.1016/j.vph.2018.10.009 .

Sun, Wen-Tao, Wang, Xiang-Chong, Novaković, Aleksandra, Wang, Jun, He, Guo-Wei, Yang, Qin, "Protection of dilator function of coronary arteries from homocysteine by tetramethylpyrazine: Role of ER stress in modulation of BKCa channels" in Vibrational Spectroscopy, 113 (2019):27-37,
https://doi.org/10.1016/j.vph.2018.10.009 . .

TY  - JOUR
AU  - Stojanović, Ivan
AU  - Kaitović, Marko
AU  - Novaković, Aleksandra
AU  - Vuković, Petar
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3273
AB  - Introduction. Mitral valve calcifications are frequent finding in Barlow disease. This is making mitral repair surgery even more demanding in already complex valve pathology. Case report. A fifty-five-year-old Barlow disease patient underwent a mitral repair surgery due to posterior leaflet prolapse at P2 level and extensive posterior leaflet and annular calcifications as well. The prolapsed scallop was resected, while P1 and P3 scallops were detached from the annulus. After complete posterior annulus decalcification, so formed the large atrio-ventricular defect was reconstructed with the autologous pericardial patch and double suture line technique. The P1 and P3 segments were reattached there by the sliding technique and sutured with no strain. Annuloplasty was performed with a saddle rigid ring No 36. The patient was discharged nine days after the surgery with just a trace of mitral regurgitation. Conclusion. Annular decalcification and reconstruction in the patients with calcified Barlow mitral disease is necessary for safe and durable mitral valve surgical repair.
AB  - Uvod. Kalcifikacije mitralne valvule su čest nalaz kod bolesnika sa Barlovljevom bolesti što čini rekonstruktivnu hirurgiju zalistka kod ovih bolesnika znatno složenijom. Prikaz bolesnika. Bolesniku starom 55 godina je urađena rekonstrukcija mitralnog zalistka zbog prolapsa posteriornog listića i značajnih kalcifikacija na P2 segmentu i posteriornom anulusu. Nakon resekcije P2 segmenta i odvajanja P1 i P3 segmenta od anulusa, urađena je kompletna resekcija velikog kalcifikata sa skoro polovine obima posteriornog anulusa. Nastali atrioventrikularnog defekt rekonstruisan je autolognim perikardom elipsoidnog oblika sašivenim u dva sloja. P1 i P3 segment su potom reinplantirani na rekonstruisani anulus i međusobno spojeni. Rekonstruktivna procedura je kompletirana anuloplastikom pomoću sedlastog rigidnog prstena veličine 36. Bolesnik je otpušten devetog postoperativnog dana sa neznatnom mitralnom regurgitacijom. Zaključak. Dekalcifikacija posteriornog anulusa uz preciznu rekonstrukciju nastalog atrioventikularnog defekta je neophodna procedura za bezbednu i funkcionalno trajnu rekonstrukciju mitralnog zalistka.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Reconstructive surgery of an extremely calcified mitral valve in a Barlow disease patient: A case report
T1  - Rekonstruktivna hirurgija ekstremno kalcifikovane mitralne valvule kod bolesnika sa Barlovljevom bolesti
VL  - 76
IS  - 5
SP  - 552
EP  - 554
DO  - 10.2298/VSP170312117S
ER  - 

@article{
author = "Stojanović, Ivan and Kaitović, Marko and Novaković, Aleksandra and Vuković, Petar",
year = "2019",
abstract = "Introduction. Mitral valve calcifications are frequent finding in Barlow disease. This is making mitral repair surgery even more demanding in already complex valve pathology. Case report. A fifty-five-year-old Barlow disease patient underwent a mitral repair surgery due to posterior leaflet prolapse at P2 level and extensive posterior leaflet and annular calcifications as well. The prolapsed scallop was resected, while P1 and P3 scallops were detached from the annulus. After complete posterior annulus decalcification, so formed the large atrio-ventricular defect was reconstructed with the autologous pericardial patch and double suture line technique. The P1 and P3 segments were reattached there by the sliding technique and sutured with no strain. Annuloplasty was performed with a saddle rigid ring No 36. The patient was discharged nine days after the surgery with just a trace of mitral regurgitation. Conclusion. Annular decalcification and reconstruction in the patients with calcified Barlow mitral disease is necessary for safe and durable mitral valve surgical repair., Uvod. Kalcifikacije mitralne valvule su čest nalaz kod bolesnika sa Barlovljevom bolesti što čini rekonstruktivnu hirurgiju zalistka kod ovih bolesnika znatno složenijom. Prikaz bolesnika. Bolesniku starom 55 godina je urađena rekonstrukcija mitralnog zalistka zbog prolapsa posteriornog listića i značajnih kalcifikacija na P2 segmentu i posteriornom anulusu. Nakon resekcije P2 segmenta i odvajanja P1 i P3 segmenta od anulusa, urađena je kompletna resekcija velikog kalcifikata sa skoro polovine obima posteriornog anulusa. Nastali atrioventrikularnog defekt rekonstruisan je autolognim perikardom elipsoidnog oblika sašivenim u dva sloja. P1 i P3 segment su potom reinplantirani na rekonstruisani anulus i međusobno spojeni. Rekonstruktivna procedura je kompletirana anuloplastikom pomoću sedlastog rigidnog prstena veličine 36. Bolesnik je otpušten devetog postoperativnog dana sa neznatnom mitralnom regurgitacijom. Zaključak. Dekalcifikacija posteriornog anulusa uz preciznu rekonstrukciju nastalog atrioventikularnog defekta je neophodna procedura za bezbednu i funkcionalno trajnu rekonstrukciju mitralnog zalistka.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Reconstructive surgery of an extremely calcified mitral valve in a Barlow disease patient: A case report, Rekonstruktivna hirurgija ekstremno kalcifikovane mitralne valvule kod bolesnika sa Barlovljevom bolesti",
volume = "76",
number = "5",
pages = "552-554",
doi = "10.2298/VSP170312117S"
}

Stojanović, I., Kaitović, M., Novaković, A.,& Vuković, P.. (2019). Reconstructive surgery of an extremely calcified mitral valve in a Barlow disease patient: A case report. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 76(5), 552-554.
https://doi.org/10.2298/VSP170312117S

Stojanović I, Kaitović M, Novaković A, Vuković P. Reconstructive surgery of an extremely calcified mitral valve in a Barlow disease patient: A case report. in Vojnosanitetski pregled. 2019;76(5):552-554.
doi:10.2298/VSP170312117S .

Stojanović, Ivan, Kaitović, Marko, Novaković, Aleksandra, Vuković, Petar, "Reconstructive surgery of an extremely calcified mitral valve in a Barlow disease patient: A case report" in Vojnosanitetski pregled, 76, no. 5 (2019):552-554,
https://doi.org/10.2298/VSP170312117S . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Janković, Goran
AU  - Nenezić, Dragoslav
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3072
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Cardioprotective effect of procyanidin B2
VL  - 275
SP  - e72
EP  - e72
DO  - 10.1016/j.atherosclerosis.2018.06.200
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Janković, Goran and Nenezić, Dragoslav and Stojanović, Ivan and Milojević, Predrag and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2018",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Cardioprotective effect of procyanidin B2",
volume = "275",
pages = "e72-e72",
doi = "10.1016/j.atherosclerosis.2018.06.200"
}

Novaković, A., Marinko, M., Janković, G., Nenezić, D., Stojanović, I., Milojević, P., Kanjuh, V., Yang, Q.,& He, G.. (2018). Cardioprotective effect of procyanidin B2. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 275, e72-e72.
https://doi.org/10.1016/j.atherosclerosis.2018.06.200

Novaković A, Marinko M, Janković G, Nenezić D, Stojanović I, Milojević P, Kanjuh V, Yang Q, He G. Cardioprotective effect of procyanidin B2. in Atherosclerosis. 2018;275:e72-e72.
doi:10.1016/j.atherosclerosis.2018.06.200 .

Novaković, Aleksandra, Marinko, Marija, Janković, Goran, Nenezić, Dragoslav, Stojanović, Ivan, Milojević, Predrag, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Cardioprotective effect of procyanidin B2" in Atherosclerosis, 275 (2018):e72-e72,
https://doi.org/10.1016/j.atherosclerosis.2018.06.200 . .

TY  - JOUR
AU  - Marinko, Marija
AU  - Janković, Goran
AU  - Nenezić, Dragoslav
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Kanjuh, Vladimir
AU  - Novaković, Aleksandra
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3191
AB  - In this study, we aimed to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human saphenous vein (HSV), as a part of its cardioprotective action, and to define the mechanisms underlying this vasorelaxation. (-)-Epicatechin induced a concentration-dependent relaxation of HSV pre-contracted by phenylephrine. Among K+ channel blockers, 4-aminopyridine, margatoxin, and iberiotoxin significantly inhibited relaxation of HSV, while glibenclamide considerably reduced effects of the high concentrations of (-)-epicatechin. Additionally, (-)-epicatechin relaxed contraction induced by 80 mM K+, whereas in the presence of nifedipine produced partial relaxation of HSV rings pre-contracted by phenylephrine. In Ca2+-free solution, (-)-epicatechin relaxed contraction induced by phenylephrine, but had no effect on contraction induced by caffeine. A sarcoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, significantly reduced relaxation of HSV produced by (-)-epicatechin. These results demonstrate that (-)-epicatechin produces endothelium-independent relaxation of isolated HSV rings. Vasorelaxation to (-)-epicatechin probably involves activation of 4-aminopyridine- and margatoxin-sensitive K-V channels, BKCa channels, and at least partly, K-ATP channels. In addition, not only the inhibition of extracellular Ca2+ influx, but regulation of the intracellular Ca2+ release, via inositol-trisphosphate receptors and reuptake into sarcoplasmic reticulum, via stimulation of Ca2+-ATPase, as well, most likely participate in (-)-epicatechin-induced relaxation of HSV.
PB  - Wiley, Hoboken
T2  - Phytotherapy Research
T1  - (-)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels
VL  - 32
IS  - 2
SP  - 267
EP  - 275
DO  - 10.1002/ptr.5969
ER  - 

@article{
author = "Marinko, Marija and Janković, Goran and Nenezić, Dragoslav and Milojević, Predrag and Stojanović, Ivan and Kanjuh, Vladimir and Novaković, Aleksandra",
year = "2018",
abstract = "In this study, we aimed to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human saphenous vein (HSV), as a part of its cardioprotective action, and to define the mechanisms underlying this vasorelaxation. (-)-Epicatechin induced a concentration-dependent relaxation of HSV pre-contracted by phenylephrine. Among K+ channel blockers, 4-aminopyridine, margatoxin, and iberiotoxin significantly inhibited relaxation of HSV, while glibenclamide considerably reduced effects of the high concentrations of (-)-epicatechin. Additionally, (-)-epicatechin relaxed contraction induced by 80 mM K+, whereas in the presence of nifedipine produced partial relaxation of HSV rings pre-contracted by phenylephrine. In Ca2+-free solution, (-)-epicatechin relaxed contraction induced by phenylephrine, but had no effect on contraction induced by caffeine. A sarcoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, significantly reduced relaxation of HSV produced by (-)-epicatechin. These results demonstrate that (-)-epicatechin produces endothelium-independent relaxation of isolated HSV rings. Vasorelaxation to (-)-epicatechin probably involves activation of 4-aminopyridine- and margatoxin-sensitive K-V channels, BKCa channels, and at least partly, K-ATP channels. In addition, not only the inhibition of extracellular Ca2+ influx, but regulation of the intracellular Ca2+ release, via inositol-trisphosphate receptors and reuptake into sarcoplasmic reticulum, via stimulation of Ca2+-ATPase, as well, most likely participate in (-)-epicatechin-induced relaxation of HSV.",
publisher = "Wiley, Hoboken",
journal = "Phytotherapy Research",
title = "(-)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels",
volume = "32",
number = "2",
pages = "267-275",
doi = "10.1002/ptr.5969"
}

Marinko, M., Janković, G., Nenezić, D., Milojević, P., Stojanović, I., Kanjuh, V.,& Novaković, A.. (2018). (-)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels. in Phytotherapy Research
Wiley, Hoboken., 32(2), 267-275.
https://doi.org/10.1002/ptr.5969

Marinko M, Janković G, Nenezić D, Milojević P, Stojanović I, Kanjuh V, Novaković A. (-)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels. in Phytotherapy Research. 2018;32(2):267-275.
doi:10.1002/ptr.5969 .

Marinko, Marija, Janković, Goran, Nenezić, Dragoslav, Milojević, Predrag, Stojanović, Ivan, Kanjuh, Vladimir, Novaković, Aleksandra, "(-)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels" in Phytotherapy Research, 32, no. 2 (2018):267-275,
https://doi.org/10.1002/ptr.5969 . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Milojević, Predrag
AU  - Kanjuh, Vladimir
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3114
AB  - Dyslipidemia is the leading risk factor for the development of atherosclerosis and associated consequences, such as coronary heart disease, ischemic cerebrovascular and peripheral vascular disease. These diseases are the major cause of mortality in the world and in Europe as well, where they are responsible for around 45% of all deaths. Treatment of dyslipidemia includes the use of statins, ezetimibe, fibrates, niacin, bile acids sequestrants and omega-3 fatty acids. Although statins play the major role in dyslipidemia treatment by reducing the risk of cardiovascular (CV) events by 30%, there is a need for additional new drugs that reduce the residual risk even more. PCSK9 inhibitors, apolipoprotein B (apoB) synthesis inhibitors, MTP inhibitors and CETP inhibitors are already approved for the specific indications, or are in the advanced stages of clinical investigation. Two PCSK9 inhibitors, alirocumab and evolocumab are approved for use in combination with statins for the treatment of heterozygous familial hypercholesterolemia (FH), but also in patients with clinical atherosclerotic CV diseases who require additional low-density lipoprotein cholesterol (LDL-C) level reduction. In addition, evolocumab is approved for use in patients with homozygous FH. Mipomersen, apoB synthesis inhibitor, lomitapide, and oral MTP inhibitor are currently approved in the treatment of patients with homozygous FH as an adjunct to the maximum tolerated doses of statins and other lipid-lowering drugs. Although the new lipid-lowering agents produce significant LDL-C level reduction, more clinical studies are necessary to confirm their efficacy and safety in dyslipidemia treatment.
AB  - Dislipidemije su vodeći faktor rizika za razvoj ateroskleroze i njenih posledica, kao što su koronarna bolest srca, ishemična cerebrovaskularna i periferna vaskularna bolest. Ove bolesti su glavni uzrok mortaliteta, kako u svetu tako i u Evropi, gde su odgovorne za 45% ukupne smrtnosti. Terapija dislipidemija uključuje primenu: statina, ezetimiba, fibrata, niacina, smola koje vezuju žučne kiseline i omega-3 masnih kiselina. Od pomenutih lekova, vodeću ulogu u terapiji dislipidemija imaju statini. Treba istaći da uprkos primeni statina, koji redukuju rizik od pojave kardiovaskularnih (KV) događaja za oko 30%, još uvek ostaje tzv. rezidualni rizik za nastanak KV događaja, što ukazuje da su potrebni novi lekovi koji će dalje redukovati rezidualni rizik. Novi lekovi u terapiji dislipidemija uključuju PCSK9 inhibitore, inhibitore sinteze apolipoproteina B (apoB), MTP inhibitore i CETP inhibitore, koji su ili već odobreni za primenu u određenim indikacijama, ili se nalaze u odmaklim fazama kliničkog ispitivanja. Alirokumab i evolokumab, dva PCSK9 inhibitora, odobrena su za primenu, u kombinaciji sa statinima, u terapiji heterozigotne familijarne hiperholesterolemije (FH), kao i kod bolesnika sa kliničkim aterosklerotičnim KV bolestima koji zahtevaju dodatnu redukciju nivoa lipoproteina male gustine (low-density lipoprotein cholesterol, LDL-C). Pored toga, evolokumab je odobren za primenu kod bolesnika sa homozigotnom FH. Mipomersen, inhibitor sinteze apoB, i lomitapid, oralni MTP inhibitor, su, odobreni za primenu samo kod bolesnika sa homozigotnom FH kao dodatak maksimalnoj tolerišućoj dozi statina i drugih hipolipemika. Iako novi hipolipemici značajno redukuju nivo LDL-C, neophodno je sprovesti studije, duže i sa većim brojem ispitanika, koje će potvrditi njihovu efikasnost i bezbednost i time omogućiti njihovu širu primenu u terapiji dislipidemija.
PB  - Univerzitet u Nišu - Medicinski fakultet, Niš
T2  - Acta medica Medianae
T1  - New drugs for the treatment of dyslipidemia
T1  - Novi lekovi u terapiji dislipidemija
VL  - 57
IS  - 1
SP  - 54
EP  - 63
DO  - 10.5633/amm.2018.0109
ER  - 

@article{
author = "Novaković, Aleksandra and Marinko, Marija and Stojanović, Ivan and Nenezić, Dragoslav and Milojević, Predrag and Kanjuh, Vladimir",
year = "2018",
abstract = "Dyslipidemia is the leading risk factor for the development of atherosclerosis and associated consequences, such as coronary heart disease, ischemic cerebrovascular and peripheral vascular disease. These diseases are the major cause of mortality in the world and in Europe as well, where they are responsible for around 45% of all deaths. Treatment of dyslipidemia includes the use of statins, ezetimibe, fibrates, niacin, bile acids sequestrants and omega-3 fatty acids. Although statins play the major role in dyslipidemia treatment by reducing the risk of cardiovascular (CV) events by 30%, there is a need for additional new drugs that reduce the residual risk even more. PCSK9 inhibitors, apolipoprotein B (apoB) synthesis inhibitors, MTP inhibitors and CETP inhibitors are already approved for the specific indications, or are in the advanced stages of clinical investigation. Two PCSK9 inhibitors, alirocumab and evolocumab are approved for use in combination with statins for the treatment of heterozygous familial hypercholesterolemia (FH), but also in patients with clinical atherosclerotic CV diseases who require additional low-density lipoprotein cholesterol (LDL-C) level reduction. In addition, evolocumab is approved for use in patients with homozygous FH. Mipomersen, apoB synthesis inhibitor, lomitapide, and oral MTP inhibitor are currently approved in the treatment of patients with homozygous FH as an adjunct to the maximum tolerated doses of statins and other lipid-lowering drugs. Although the new lipid-lowering agents produce significant LDL-C level reduction, more clinical studies are necessary to confirm their efficacy and safety in dyslipidemia treatment., Dislipidemije su vodeći faktor rizika za razvoj ateroskleroze i njenih posledica, kao što su koronarna bolest srca, ishemična cerebrovaskularna i periferna vaskularna bolest. Ove bolesti su glavni uzrok mortaliteta, kako u svetu tako i u Evropi, gde su odgovorne za 45% ukupne smrtnosti. Terapija dislipidemija uključuje primenu: statina, ezetimiba, fibrata, niacina, smola koje vezuju žučne kiseline i omega-3 masnih kiselina. Od pomenutih lekova, vodeću ulogu u terapiji dislipidemija imaju statini. Treba istaći da uprkos primeni statina, koji redukuju rizik od pojave kardiovaskularnih (KV) događaja za oko 30%, još uvek ostaje tzv. rezidualni rizik za nastanak KV događaja, što ukazuje da su potrebni novi lekovi koji će dalje redukovati rezidualni rizik. Novi lekovi u terapiji dislipidemija uključuju PCSK9 inhibitore, inhibitore sinteze apolipoproteina B (apoB), MTP inhibitore i CETP inhibitore, koji su ili već odobreni za primenu u određenim indikacijama, ili se nalaze u odmaklim fazama kliničkog ispitivanja. Alirokumab i evolokumab, dva PCSK9 inhibitora, odobrena su za primenu, u kombinaciji sa statinima, u terapiji heterozigotne familijarne hiperholesterolemije (FH), kao i kod bolesnika sa kliničkim aterosklerotičnim KV bolestima koji zahtevaju dodatnu redukciju nivoa lipoproteina male gustine (low-density lipoprotein cholesterol, LDL-C). Pored toga, evolokumab je odobren za primenu kod bolesnika sa homozigotnom FH. Mipomersen, inhibitor sinteze apoB, i lomitapid, oralni MTP inhibitor, su, odobreni za primenu samo kod bolesnika sa homozigotnom FH kao dodatak maksimalnoj tolerišućoj dozi statina i drugih hipolipemika. Iako novi hipolipemici značajno redukuju nivo LDL-C, neophodno je sprovesti studije, duže i sa većim brojem ispitanika, koje će potvrditi njihovu efikasnost i bezbednost i time omogućiti njihovu širu primenu u terapiji dislipidemija.",
publisher = "Univerzitet u Nišu - Medicinski fakultet, Niš",
journal = "Acta medica Medianae",
title = "New drugs for the treatment of dyslipidemia, Novi lekovi u terapiji dislipidemija",
volume = "57",
number = "1",
pages = "54-63",
doi = "10.5633/amm.2018.0109"
}

Novaković, A., Marinko, M., Stojanović, I., Nenezić, D., Milojević, P.,& Kanjuh, V.. (2018). New drugs for the treatment of dyslipidemia. in Acta medica Medianae
Univerzitet u Nišu - Medicinski fakultet, Niš., 57(1), 54-63.
https://doi.org/10.5633/amm.2018.0109

Novaković A, Marinko M, Stojanović I, Nenezić D, Milojević P, Kanjuh V. New drugs for the treatment of dyslipidemia. in Acta medica Medianae. 2018;57(1):54-63.
doi:10.5633/amm.2018.0109 .

Novaković, Aleksandra, Marinko, Marija, Stojanović, Ivan, Nenezić, Dragoslav, Milojević, Predrag, Kanjuh, Vladimir, "New drugs for the treatment of dyslipidemia" in Acta medica Medianae, 57, no. 1 (2018):54-63,
https://doi.org/10.5633/amm.2018.0109 . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2972
AB  - The aim of the present study was to investigate and characterize vasorelaxant effect of procyanidin B2 on human internal mammary artery (HIMA) as one of the mechanisms of its protective effect against vascular risk. Procyanidin B2 induced strong concentration-dependent relaxation of HIMA rings pre-contracted by phenylephrine. Pretreatment with L-NAME, a NO synthase inhibitor, hydroxocobalamin, a NO scavenger, and ODQ, an inhibitor of soluble guanylate cyclase, significantly inhibited procyanidin B2-induced relaxation of HIMA, while indomethacin, a cyclooxygenase inhibitor, considerably reduced effects of low concentrations. Among K+ channel blockers, iberiotoxin, a selective blocker of large conductance Ca2+-activated K+ channels (BKCa), abolished procyanidin B2-induced relaxation, glibenclamide, a selective ATP-sensitive K+(K-ATP) channels blocker, induced partial inhibition, while 4-aminopyridine, a blocker of voltage-gated K+(K-V) channels, and TRAM-34, an inhibitor of intermediate-conductance Ca2+-activated K+(IKCa) channels, slightly reduced maximal relaxation of HIMA. Further, procyanidin B2 relaxed contraction induced by phenylephrine in Ca2+-free Krebs solution, but had no effect on contraction induced by caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, significantly reduced relaxation of HIMA produced by procyanidin B2. These results demonstrate that procyanidin B2 produces endothelium-dependent relaxation of HIMA pre-contracted by phenylephrine. This effect is primarily the result of an increased NO synthesis and secretion by endothelial cells and partially of prostacyclin, although it involves activation of BKCa and K-ATP, as well as K-V and IKCa channels in high concentrations of procyanidin B2.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmacology
T1  - Endothelium-dependent vasorelaxant effect of procyanidin B2 on human internal mammary artery
VL  - 807
SP  - 75
EP  - 81
DO  - 10.1016/j.ejphar.2017.04.015
ER  - 

@article{
author = "Novaković, Aleksandra and Marinko, Marija and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Nenezić, Dragoslav and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2017",
abstract = "The aim of the present study was to investigate and characterize vasorelaxant effect of procyanidin B2 on human internal mammary artery (HIMA) as one of the mechanisms of its protective effect against vascular risk. Procyanidin B2 induced strong concentration-dependent relaxation of HIMA rings pre-contracted by phenylephrine. Pretreatment with L-NAME, a NO synthase inhibitor, hydroxocobalamin, a NO scavenger, and ODQ, an inhibitor of soluble guanylate cyclase, significantly inhibited procyanidin B2-induced relaxation of HIMA, while indomethacin, a cyclooxygenase inhibitor, considerably reduced effects of low concentrations. Among K+ channel blockers, iberiotoxin, a selective blocker of large conductance Ca2+-activated K+ channels (BKCa), abolished procyanidin B2-induced relaxation, glibenclamide, a selective ATP-sensitive K+(K-ATP) channels blocker, induced partial inhibition, while 4-aminopyridine, a blocker of voltage-gated K+(K-V) channels, and TRAM-34, an inhibitor of intermediate-conductance Ca2+-activated K+(IKCa) channels, slightly reduced maximal relaxation of HIMA. Further, procyanidin B2 relaxed contraction induced by phenylephrine in Ca2+-free Krebs solution, but had no effect on contraction induced by caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, significantly reduced relaxation of HIMA produced by procyanidin B2. These results demonstrate that procyanidin B2 produces endothelium-dependent relaxation of HIMA pre-contracted by phenylephrine. This effect is primarily the result of an increased NO synthesis and secretion by endothelial cells and partially of prostacyclin, although it involves activation of BKCa and K-ATP, as well as K-V and IKCa channels in high concentrations of procyanidin B2.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmacology",
title = "Endothelium-dependent vasorelaxant effect of procyanidin B2 on human internal mammary artery",
volume = "807",
pages = "75-81",
doi = "10.1016/j.ejphar.2017.04.015"
}

Novaković, A., Marinko, M., Janković, G., Stojanović, I., Milojević, P., Nenezić, D., Kanjuh, V., Yang, Q.,& He, G.. (2017). Endothelium-dependent vasorelaxant effect of procyanidin B2 on human internal mammary artery. in European Journal of Pharmacology
Elsevier Science BV, Amsterdam., 807, 75-81.
https://doi.org/10.1016/j.ejphar.2017.04.015

Novaković A, Marinko M, Janković G, Stojanović I, Milojević P, Nenezić D, Kanjuh V, Yang Q, He G. Endothelium-dependent vasorelaxant effect of procyanidin B2 on human internal mammary artery. in European Journal of Pharmacology. 2017;807:75-81.
doi:10.1016/j.ejphar.2017.04.015 .

Novaković, Aleksandra, Marinko, Marija, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Nenezić, Dragoslav, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Endothelium-dependent vasorelaxant effect of procyanidin B2 on human internal mammary artery" in European Journal of Pharmacology, 807 (2017):75-81,
https://doi.org/10.1016/j.ejphar.2017.04.015 . .

TY  - JOUR
AU  - Novaković, Aleksandra
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2944
AB  - Inflammatory bowel disease (IBD) is an idiopathic chronic disease. According to the latest data, about 2.5 million people in Europe, as well about 8 thousands in Serbia, have IBD. The main symptoms of this disease are diarrhoea, abdominal pain, bleeding, anaemia and weight loss. The two major form of IBD are ulcerative colitis and Crohn's disease. There is no drug that would lead to complete healing of IBC. The goals of the therapy include introducing remission, maintaining remission, minimizing side effects of drugs and improving the quality of life. The IBC therapy includes the use of drugs such as: aminosalicylates, glucocorticoids, immunosuppressants, and biologics. As an initial therapy in the treatment of ulcerative colitis, aminosalicylates are the most commonly used, and maintenance therapy is recommended for all patients. Drugs of the first choice for maintenance of remission are also aminosalicylates. For the treatment of Crohn's disease, first-line drugs are glucocorticoids. Maintenance therapy is not mandatory for all patients with Crohn's disease. If maintenance therapy is necessary, immunosuppressors (azathioprine or methotrexate), as well as biologic agents (anti-TNF drugs or anti-integrin medications), are used.
AB  - Inflamatorna bolest creva (IBC) je idiopatska hronična bolest. Prema najnovijim podacima, od IBC u Evropi je obolelo oko 2,5 miliona ljudi, a u Srbiji oko 8 hiljada. Glavni simptomi ove bolesti su dijareja, abdominalni bol, krvarenje, anemija i gubitak telesne težine. Dva glavna oblika IBC su ulcerozni kolitis i Kronova bolest. Za IBC nema leka koji će dovesti do potpunog izlečenja. Ciljevi terapije uključuju uvođenje u remisiju, održavanje remisije, minimalizaciju sporednih efekata lekova i poboljšanje kvaliteta života. Terapija IBC uključuje primenu lekova kao što su: aminosalicilati, glukokortikoidi, imunosupresori, kao i biološki lekovi. Kao inicijalna terapija u lečenju ulceroznog kolitisa najčešće se koriste aminosalicilati, a terapija održavanja remisije se preporučuje svim pacijentima. Lekovi prvog izbora u održavanju remisije su, takođe, aminosalicilati. Za terapiju Kronove bolesti lekovi prvog izbora su glukokortikoidi. Terapija održavanja remisije nije obavezna za sve pacijente sa Kronovom bolešću. Ukoliko je terapija održavanja neophodna, koriste se imunosupresori (azatioprin ili metotreksat), kao i biološki lekovi (anti-TNF lekovi ili anti-integrinski lekovi).
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Modern therapy for inflammatory bowel disease
T1  - Savremena terapija inflamatorne bolesti creva
VL  - 67
IS  - 2
SP  - 112
EP  - 123
DO  - 10.5937/arhfarm1702112N
ER  - 

@article{
author = "Novaković, Aleksandra",
year = "2017",
abstract = "Inflammatory bowel disease (IBD) is an idiopathic chronic disease. According to the latest data, about 2.5 million people in Europe, as well about 8 thousands in Serbia, have IBD. The main symptoms of this disease are diarrhoea, abdominal pain, bleeding, anaemia and weight loss. The two major form of IBD are ulcerative colitis and Crohn's disease. There is no drug that would lead to complete healing of IBC. The goals of the therapy include introducing remission, maintaining remission, minimizing side effects of drugs and improving the quality of life. The IBC therapy includes the use of drugs such as: aminosalicylates, glucocorticoids, immunosuppressants, and biologics. As an initial therapy in the treatment of ulcerative colitis, aminosalicylates are the most commonly used, and maintenance therapy is recommended for all patients. Drugs of the first choice for maintenance of remission are also aminosalicylates. For the treatment of Crohn's disease, first-line drugs are glucocorticoids. Maintenance therapy is not mandatory for all patients with Crohn's disease. If maintenance therapy is necessary, immunosuppressors (azathioprine or methotrexate), as well as biologic agents (anti-TNF drugs or anti-integrin medications), are used., Inflamatorna bolest creva (IBC) je idiopatska hronična bolest. Prema najnovijim podacima, od IBC u Evropi je obolelo oko 2,5 miliona ljudi, a u Srbiji oko 8 hiljada. Glavni simptomi ove bolesti su dijareja, abdominalni bol, krvarenje, anemija i gubitak telesne težine. Dva glavna oblika IBC su ulcerozni kolitis i Kronova bolest. Za IBC nema leka koji će dovesti do potpunog izlečenja. Ciljevi terapije uključuju uvođenje u remisiju, održavanje remisije, minimalizaciju sporednih efekata lekova i poboljšanje kvaliteta života. Terapija IBC uključuje primenu lekova kao što su: aminosalicilati, glukokortikoidi, imunosupresori, kao i biološki lekovi. Kao inicijalna terapija u lečenju ulceroznog kolitisa najčešće se koriste aminosalicilati, a terapija održavanja remisije se preporučuje svim pacijentima. Lekovi prvog izbora u održavanju remisije su, takođe, aminosalicilati. Za terapiju Kronove bolesti lekovi prvog izbora su glukokortikoidi. Terapija održavanja remisije nije obavezna za sve pacijente sa Kronovom bolešću. Ukoliko je terapija održavanja neophodna, koriste se imunosupresori (azatioprin ili metotreksat), kao i biološki lekovi (anti-TNF lekovi ili anti-integrinski lekovi).",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Modern therapy for inflammatory bowel disease, Savremena terapija inflamatorne bolesti creva",
volume = "67",
number = "2",
pages = "112-123",
doi = "10.5937/arhfarm1702112N"
}

Novaković, A.. (2017). Modern therapy for inflammatory bowel disease. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 67(2), 112-123.
https://doi.org/10.5937/arhfarm1702112N

Novaković A. Modern therapy for inflammatory bowel disease. in Arhiv za farmaciju. 2017;67(2):112-123.
doi:10.5937/arhfarm1702112N .

Novaković, Aleksandra, "Modern therapy for inflammatory bowel disease" in Arhiv za farmaciju, 67, no. 2 (2017):112-123,
https://doi.org/10.5937/arhfarm1702112N . .

TY  - JOUR
AU  - Tomić, Milan
AU  - Novaković, Aleksandra
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
AU  - Stojanović, Ivan
AU  - Gajin, Predrag
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2936
AB  - More than 50 years ago, vitamin K antagonists were the only available oral anticoagulants. Since their application involves a number of limitations, it was necessary to develop new oral anticoagulant drugs and introduce them into clinical practice. These drugs have many advantages over vitamin K antagonists, including rapid onset/offset, a small number of interactions with other drugs and food, simplified dosing and predictable pharmacokinetics, eliminating the need for daily laboratory monitoring. In addition, new oral anticoagulant drugs act selectively on a single coagulation factor. Currently, the following drugs are approved for use: direct thrombin inhibitor, dabigatran etexilate, direct factor Xa inhibitor, rivaroxaban, apixaban and edoxaban. Dabigatran etexilate and apixaban are approved for the primary prevention of venous thromboembolism in adult patients undergoing elective surgery of total hip or knee replacement, while in addition to these anticoagulants edoxaban is approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment and prevention of recurrent deep vein thrombosis dabigatran etexilate, rivaroxaban and edoxaban are approved. In addition, rivaroxaban is approved for the secondary prevention of atherothrombotic events in patients with acute coronary syndrome.
AB  - Više od 50 godina, antagonisti vitamina K bili su jedini dostupni oralni antikoagulantni lekovi. S obzirom na to da njihova primena podrazumeva brojna ograničenja, bilo je neophodno razviti i uvesti u kliničku praksu nove oralne antikoagulantne lekove. Ovi lekovi imaju brojne prednosti u poređenju s antagonistima vitamina K, koje uključuju brz početak i prestanak dejstva, mali broj interakcija s drugim lekovima i hranom, pojednostavljen način doziranja, kao i predvidivu farmakokinetiku, čime se eliminiše potreba za svakodnevnim laboratorijskim praćenjem. Osim toga, novi oralni antikoagulantni lekovi deluju selektivno samo na jedan faktor koagulacije. Trenutno su odobreni za upotrebu direktni inhibitor trombina, dabigatran eteksilat, kao i direktni inhibitori faktora Xa, rivaroksaban, edoksaban i apiksaban. Dabigatran eteksilat i apiksaban odobreni su za primarnu prevenciju venske tromboembolije kod odraslih pacijenata koji se podvrgavaju elektivnom hirurškom zahvatu totalne zamene kuka ili kolena, dok je za prevenciju moždanog udara i sistemske embolije kod odraslih pacijenata sa nevalvularnom atrijalnom fibrilacijom, pored navedenih antikoagulantnih lekova, odobren i edoksaban. Za terapiju i prevenciju rekurentne duboke venske tromboze odobreni su dabigatran eteksilat, rivaroksaban i edoksaban. Osim toga, rivaroksaban je odobren i za sekundarnu prevenciju aterotrombotičkih događaja nakon akutnog koronarnog sindroma.
PB  - Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac
T2  - Medicinski časopis
T1  - Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases
T1  - Direktni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolesti
VL  - 51
IS  - 3
SP  - 89
EP  - 97
DO  - 10.5937/mckg51-15563
ER  - 

@article{
author = "Tomić, Milan and Novaković, Aleksandra and Milojević, Predrag and Nenezić, Dragoslav and Stojanović, Ivan and Gajin, Predrag",
year = "2017",
abstract = "More than 50 years ago, vitamin K antagonists were the only available oral anticoagulants. Since their application involves a number of limitations, it was necessary to develop new oral anticoagulant drugs and introduce them into clinical practice. These drugs have many advantages over vitamin K antagonists, including rapid onset/offset, a small number of interactions with other drugs and food, simplified dosing and predictable pharmacokinetics, eliminating the need for daily laboratory monitoring. In addition, new oral anticoagulant drugs act selectively on a single coagulation factor. Currently, the following drugs are approved for use: direct thrombin inhibitor, dabigatran etexilate, direct factor Xa inhibitor, rivaroxaban, apixaban and edoxaban. Dabigatran etexilate and apixaban are approved for the primary prevention of venous thromboembolism in adult patients undergoing elective surgery of total hip or knee replacement, while in addition to these anticoagulants edoxaban is approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment and prevention of recurrent deep vein thrombosis dabigatran etexilate, rivaroxaban and edoxaban are approved. In addition, rivaroxaban is approved for the secondary prevention of atherothrombotic events in patients with acute coronary syndrome., Više od 50 godina, antagonisti vitamina K bili su jedini dostupni oralni antikoagulantni lekovi. S obzirom na to da njihova primena podrazumeva brojna ograničenja, bilo je neophodno razviti i uvesti u kliničku praksu nove oralne antikoagulantne lekove. Ovi lekovi imaju brojne prednosti u poređenju s antagonistima vitamina K, koje uključuju brz početak i prestanak dejstva, mali broj interakcija s drugim lekovima i hranom, pojednostavljen način doziranja, kao i predvidivu farmakokinetiku, čime se eliminiše potreba za svakodnevnim laboratorijskim praćenjem. Osim toga, novi oralni antikoagulantni lekovi deluju selektivno samo na jedan faktor koagulacije. Trenutno su odobreni za upotrebu direktni inhibitor trombina, dabigatran eteksilat, kao i direktni inhibitori faktora Xa, rivaroksaban, edoksaban i apiksaban. Dabigatran eteksilat i apiksaban odobreni su za primarnu prevenciju venske tromboembolije kod odraslih pacijenata koji se podvrgavaju elektivnom hirurškom zahvatu totalne zamene kuka ili kolena, dok je za prevenciju moždanog udara i sistemske embolije kod odraslih pacijenata sa nevalvularnom atrijalnom fibrilacijom, pored navedenih antikoagulantnih lekova, odobren i edoksaban. Za terapiju i prevenciju rekurentne duboke venske tromboze odobreni su dabigatran eteksilat, rivaroksaban i edoksaban. Osim toga, rivaroksaban je odobren i za sekundarnu prevenciju aterotrombotičkih događaja nakon akutnog koronarnog sindroma.",
publisher = "Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac",
journal = "Medicinski časopis",
title = "Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases, Direktni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolesti",
volume = "51",
number = "3",
pages = "89-97",
doi = "10.5937/mckg51-15563"
}

Tomić, M., Novaković, A., Milojević, P., Nenezić, D., Stojanović, I.,& Gajin, P.. (2017). Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases. in Medicinski časopis
Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac., 51(3), 89-97.
https://doi.org/10.5937/mckg51-15563

Tomić M, Novaković A, Milojević P, Nenezić D, Stojanović I, Gajin P. Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases. in Medicinski časopis. 2017;51(3):89-97.
doi:10.5937/mckg51-15563 .

Tomić, Milan, Novaković, Aleksandra, Milojević, Predrag, Nenezić, Dragoslav, Stojanović, Ivan, Gajin, Predrag, "Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases" in Medicinski časopis, 51, no. 3 (2017):89-97,
https://doi.org/10.5937/mckg51-15563 . .

TY  - JOUR
AU  - Hou, Hai-Tao
AU  - Wang, Jun
AU  - Wang, Zheng-Qing
AU  - Liu, Xiao-Cheng
AU  - Marinko, Marija
AU  - Novaković, Aleksandra
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2525
AB  - Background. Graft spasm remains challenging in coronary artery bypass grafting (CABG). Calcium antagonists are commonly used in patients with coronary artery disease. This study investigated the inhibitory effect of third-generation dihydropyridine calcium channel antagonist benidipine on the vasoconstriction induced by various vasoconstrictors in the human internalmammary artery(IMA). Methods. Isolated human IMA rings (N = 65, taken from 37 patients undergoing CABG) were studied in a myograph in 2 ways: the relaxing effect of benidipine on vasoconstrictor-induced precontraction by KCl and U46619 and the depressing effect of benidipine at plasma concentrations on the contraction. Enzyme-linked immunosorbent assay (ELISA) was used to measure the change of the protein related to the L-type calcium channel. Results. Benidipine caused more relaxation in KCl-contracted (86.7% +/- 3.3%; n = 12) than in U46619-contracted (63.8% +/- 5.3%; n = 8; p  lt  0.001) IMA rings. Pretreatment of IMA with plasma concentrations of benidipine (-6.92 log M) significantly depressed subsequent contraction by KCl (from 17.3 +/- 2.7 mN to 7.4 +/- 1.2 mN; n = 6; p  lt  0.05) but did not significantly affect the contraction caused by U46619. Benidipine also caused a decrease of caveolin (CaV) 1.2 protein content (0.55 +/- 0.02 versus 0.63 +/- 0.02 mg/mL; p  lt  0.05). Conclusions. We conclude that in human IMA, the third-generation dihydropyridine calcium channel antagonist benidipine has a potent inhibitory effect on the vasoconstriction mediated by a variety of vasoconstrictors. Use of benidipine in patients undergoing CABG may provide vasorelaxant or antispastic effects in the grafts.
PB  - Elsevier Science Inc, New York
T2  - Annals of Thoracic Surgery
T1  - Effect of Benidipine in Human Internal Mammary Artery and Clinical Implications
VL  - 101
IS  - 5
SP  - 1789
EP  - 1795
DO  - 10.1016/j.athoracsur.2015.10.029
ER  - 

@article{
author = "Hou, Hai-Tao and Wang, Jun and Wang, Zheng-Qing and Liu, Xiao-Cheng and Marinko, Marija and Novaković, Aleksandra and Yang, Qin and He, Guo-Wei",
year = "2016",
abstract = "Background. Graft spasm remains challenging in coronary artery bypass grafting (CABG). Calcium antagonists are commonly used in patients with coronary artery disease. This study investigated the inhibitory effect of third-generation dihydropyridine calcium channel antagonist benidipine on the vasoconstriction induced by various vasoconstrictors in the human internalmammary artery(IMA). Methods. Isolated human IMA rings (N = 65, taken from 37 patients undergoing CABG) were studied in a myograph in 2 ways: the relaxing effect of benidipine on vasoconstrictor-induced precontraction by KCl and U46619 and the depressing effect of benidipine at plasma concentrations on the contraction. Enzyme-linked immunosorbent assay (ELISA) was used to measure the change of the protein related to the L-type calcium channel. Results. Benidipine caused more relaxation in KCl-contracted (86.7% +/- 3.3%; n = 12) than in U46619-contracted (63.8% +/- 5.3%; n = 8; p  lt  0.001) IMA rings. Pretreatment of IMA with plasma concentrations of benidipine (-6.92 log M) significantly depressed subsequent contraction by KCl (from 17.3 +/- 2.7 mN to 7.4 +/- 1.2 mN; n = 6; p  lt  0.05) but did not significantly affect the contraction caused by U46619. Benidipine also caused a decrease of caveolin (CaV) 1.2 protein content (0.55 +/- 0.02 versus 0.63 +/- 0.02 mg/mL; p  lt  0.05). Conclusions. We conclude that in human IMA, the third-generation dihydropyridine calcium channel antagonist benidipine has a potent inhibitory effect on the vasoconstriction mediated by a variety of vasoconstrictors. Use of benidipine in patients undergoing CABG may provide vasorelaxant or antispastic effects in the grafts.",
publisher = "Elsevier Science Inc, New York",
journal = "Annals of Thoracic Surgery",
title = "Effect of Benidipine in Human Internal Mammary Artery and Clinical Implications",
volume = "101",
number = "5",
pages = "1789-1795",
doi = "10.1016/j.athoracsur.2015.10.029"
}

Hou, H., Wang, J., Wang, Z., Liu, X., Marinko, M., Novaković, A., Yang, Q.,& He, G.. (2016). Effect of Benidipine in Human Internal Mammary Artery and Clinical Implications. in Annals of Thoracic Surgery
Elsevier Science Inc, New York., 101(5), 1789-1795.
https://doi.org/10.1016/j.athoracsur.2015.10.029

Hou H, Wang J, Wang Z, Liu X, Marinko M, Novaković A, Yang Q, He G. Effect of Benidipine in Human Internal Mammary Artery and Clinical Implications. in Annals of Thoracic Surgery. 2016;101(5):1789-1795.
doi:10.1016/j.athoracsur.2015.10.029 .

Hou, Hai-Tao, Wang, Jun, Wang, Zheng-Qing, Liu, Xiao-Cheng, Marinko, Marija, Novaković, Aleksandra, Yang, Qin, He, Guo-Wei, "Effect of Benidipine in Human Internal Mammary Artery and Clinical Implications" in Annals of Thoracic Surgery, 101, no. 5 (2016):1789-1795,
https://doi.org/10.1016/j.athoracsur.2015.10.029 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2442
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Epicatechin induced vasorelaxation of human internal mammary artery
VL  - 241
IS  - 1
SP  - e50
EP  - e50
DO  - 10.1016/j.atherosclerosis.2015.04.178
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Vranić, Aleksandra and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Epicatechin induced vasorelaxation of human internal mammary artery",
volume = "241",
number = "1",
pages = "e50-e50",
doi = "10.1016/j.atherosclerosis.2015.04.178"
}

Novaković, A., Marinko, M., Vranić, A., Janković, G., Stojanović, I., Milojević, P., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Epicatechin induced vasorelaxation of human internal mammary artery. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 241(1), e50-e50.
https://doi.org/10.1016/j.atherosclerosis.2015.04.178

Novaković A, Marinko M, Vranić A, Janković G, Stojanović I, Milojević P, Ugrešić N, Kanjuh V, Yang Q, He G. Epicatechin induced vasorelaxation of human internal mammary artery. in Atherosclerosis. 2015;241(1):e50-e50.
doi:10.1016/j.atherosclerosis.2015.04.178 .

Novaković, Aleksandra, Marinko, Marija, Vranić, Aleksandra, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Epicatechin induced vasorelaxation of human internal mammary artery" in Atherosclerosis, 241, no. 1 (2015):e50-e50,
https://doi.org/10.1016/j.atherosclerosis.2015.04.178 . .

TY  - JOUR
AU  - Marinko, Marija
AU  - Novaković, Aleksandra
AU  - Nenezić, Dragoslav
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Jović, Miomir
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2461
AB  - As we previously demonstrated the role of different K+ channels in the action of nicorandil on human saphenous vein (HSV) and human internal mammary artery (HIMA), this study aimed to analyse the contribution of the cGMP pathway in nicorandil-induced vasorelaxation and to determine the involvement of cGMP in the K+ channel-activating effect of nicorandil. An inhibitor of soluble guanylate cyclase (GC), ODQ, significantly inhibited nicorandil-induced relaxation, while ODQ plus glibenclamide, a selective ATP-sensitive K+ (KATP) channel inhibitor, produced a further inhibition of both vessels. In HSV, ODQ in combination with 4-aminopyridine, a blocker of voltage-gated K+ (K-V) channels, did not modify the concentration-response to nicorandil compared with ODQ, whereas in HIMA, ODQ plus iberiotoxin, a selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, produced greater inhibition than ODQ alone. We showed that the cGMP pathway plays a significant role in the vasorelaxant effect of nicorandil on HSV and HIMA. It seems that nicorandil directly opens KATP channels in both vessels and BKCa channels in HIMA, although it is possible that stimulation of GC contributes to KATP channels activation in HIMA. Contrary, the activation of K-V channels in HSV is probably due to GC activation and increased levels of cGMP.
PB  - Japanese Pharmacological Soc, Kyoto
T2  - Journal of Pharmacological Sciences
T1  - Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts
VL  - 128
IS  - 2
SP  - 59
EP  - 64
DO  - 10.1016/j.jphs.2015.03.003
ER  - 

@article{
author = "Marinko, Marija and Novaković, Aleksandra and Nenezić, Dragoslav and Stojanović, Ivan and Milojević, Predrag and Jović, Miomir and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
abstract = "As we previously demonstrated the role of different K+ channels in the action of nicorandil on human saphenous vein (HSV) and human internal mammary artery (HIMA), this study aimed to analyse the contribution of the cGMP pathway in nicorandil-induced vasorelaxation and to determine the involvement of cGMP in the K+ channel-activating effect of nicorandil. An inhibitor of soluble guanylate cyclase (GC), ODQ, significantly inhibited nicorandil-induced relaxation, while ODQ plus glibenclamide, a selective ATP-sensitive K+ (KATP) channel inhibitor, produced a further inhibition of both vessels. In HSV, ODQ in combination with 4-aminopyridine, a blocker of voltage-gated K+ (K-V) channels, did not modify the concentration-response to nicorandil compared with ODQ, whereas in HIMA, ODQ plus iberiotoxin, a selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, produced greater inhibition than ODQ alone. We showed that the cGMP pathway plays a significant role in the vasorelaxant effect of nicorandil on HSV and HIMA. It seems that nicorandil directly opens KATP channels in both vessels and BKCa channels in HIMA, although it is possible that stimulation of GC contributes to KATP channels activation in HIMA. Contrary, the activation of K-V channels in HSV is probably due to GC activation and increased levels of cGMP.",
publisher = "Japanese Pharmacological Soc, Kyoto",
journal = "Journal of Pharmacological Sciences",
title = "Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts",
volume = "128",
number = "2",
pages = "59-64",
doi = "10.1016/j.jphs.2015.03.003"
}

Marinko, M., Novaković, A., Nenezić, D., Stojanović, I., Milojević, P., Jović, M., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. in Journal of Pharmacological Sciences
Japanese Pharmacological Soc, Kyoto., 128(2), 59-64.
https://doi.org/10.1016/j.jphs.2015.03.003

Marinko M, Novaković A, Nenezić D, Stojanović I, Milojević P, Jović M, Ugrešić N, Kanjuh V, Yang Q, He G. Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. in Journal of Pharmacological Sciences. 2015;128(2):59-64.
doi:10.1016/j.jphs.2015.03.003 .

Marinko, Marija, Novaković, Aleksandra, Nenezić, Dragoslav, Stojanović, Ivan, Milojević, Predrag, Jović, Miomir, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts" in Journal of Pharmacological Sciences, 128, no. 2 (2015):59-64,
https://doi.org/10.1016/j.jphs.2015.03.003 . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2439
AB  - Evidences have suggested that flavanol compound (-)-epicatechin is associated with reduced risk of cardiovascular diseases. One of the mechanisms of its cardioprotective effect is vasodilation. However, the exact mechanisms by which (-)-epicatechin causes vasodilation are not yet clearly defined. The aims of the present study were to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human internal mammary artery (HIMA) and to determine the mechanisms underlying its vasorelaxation. Our results showed that (-)-epicatechin induced a concentration-dependent relaxation of RNA rings pre-contracted by phenylephrine. Among the K+ channel blockers, 4-aminopyricline (4-AP) and margatoxin, blockers of voltage gated K+ (K-V) channels, and glibenclamide, a selective ATP sensitive K+ (K-ATP,) channels blocker, partly inhibited the (-)-epicatechin-induced relaxation of HIMA, while iberiotoxin, a most selective blocker of large conductance Ca2+-activated K+ channels (BKCa), almost completely inhibited the relaxation. In rings pre-contracted by 80 mM K+, (-)-epicatechin induced partial relaxation of HIMA, whereas in Ca2+-free medium, (-)-epicatechin completely relaxed HIMA rings pre-contracted by phenylephrine and caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, slightly antagonized (-)-epicatechin-induced relaxation of HIMA pre-contracted by phenylephrine. These results suggest that (-)-epicatechin induces strong endothelium independent relaxation of HIMA pre-contracted by phenylephrine whilst 4-AP- and rnargatoxin-sensitive K-V channels, as well as BKCa and K-ATP channels, located in vascular smooth muscle, mediate this relaxation. In addition, it seems that (-)-epicatechin could inhibit influx of extracellular Ca2+, interfere with intracellular Ca2+ release and re uptake by the sarcoplasmic reticulum.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmacology
T1  - Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin
VL  - 762
SP  - 306
EP  - 312
DO  - 10.1016/j.ejphar.2015.05.066
ER  - 

@article{
author = "Novaković, Aleksandra and Marinko, Marija and Vranić, Aleksandra and Janković, Goran and Milojević, Predrag and Stojanović, Ivan and Nenezić, Dragoslav and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
abstract = "Evidences have suggested that flavanol compound (-)-epicatechin is associated with reduced risk of cardiovascular diseases. One of the mechanisms of its cardioprotective effect is vasodilation. However, the exact mechanisms by which (-)-epicatechin causes vasodilation are not yet clearly defined. The aims of the present study were to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human internal mammary artery (HIMA) and to determine the mechanisms underlying its vasorelaxation. Our results showed that (-)-epicatechin induced a concentration-dependent relaxation of RNA rings pre-contracted by phenylephrine. Among the K+ channel blockers, 4-aminopyricline (4-AP) and margatoxin, blockers of voltage gated K+ (K-V) channels, and glibenclamide, a selective ATP sensitive K+ (K-ATP,) channels blocker, partly inhibited the (-)-epicatechin-induced relaxation of HIMA, while iberiotoxin, a most selective blocker of large conductance Ca2+-activated K+ channels (BKCa), almost completely inhibited the relaxation. In rings pre-contracted by 80 mM K+, (-)-epicatechin induced partial relaxation of HIMA, whereas in Ca2+-free medium, (-)-epicatechin completely relaxed HIMA rings pre-contracted by phenylephrine and caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, slightly antagonized (-)-epicatechin-induced relaxation of HIMA pre-contracted by phenylephrine. These results suggest that (-)-epicatechin induces strong endothelium independent relaxation of HIMA pre-contracted by phenylephrine whilst 4-AP- and rnargatoxin-sensitive K-V channels, as well as BKCa and K-ATP channels, located in vascular smooth muscle, mediate this relaxation. In addition, it seems that (-)-epicatechin could inhibit influx of extracellular Ca2+, interfere with intracellular Ca2+ release and re uptake by the sarcoplasmic reticulum.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmacology",
title = "Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin",
volume = "762",
pages = "306-312",
doi = "10.1016/j.ejphar.2015.05.066"
}

Novaković, A., Marinko, M., Vranić, A., Janković, G., Milojević, P., Stojanović, I., Nenezić, D., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin. in European Journal of Pharmacology
Elsevier Science BV, Amsterdam., 762, 306-312.
https://doi.org/10.1016/j.ejphar.2015.05.066

Novaković A, Marinko M, Vranić A, Janković G, Milojević P, Stojanović I, Nenezić D, Ugrešić N, Kanjuh V, Yang Q, He G. Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin. in European Journal of Pharmacology. 2015;762:306-312.
doi:10.1016/j.ejphar.2015.05.066 .

Novaković, Aleksandra, Marinko, Marija, Vranić, Aleksandra, Janković, Goran, Milojević, Predrag, Stojanović, Ivan, Nenezić, Dragoslav, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin" in European Journal of Pharmacology, 762 (2015):306-312,
https://doi.org/10.1016/j.ejphar.2015.05.066 . .

TY  - JOUR
AU  - Nenezić, Dragoslav
AU  - Tanasković, Slobodan
AU  - Gajin, Predrag
AU  - Ilijevski, Nenad
AU  - Novaković, Aleksandra
AU  - Radak, Đorđe
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2423
AB  - Introduction: In this report, we aim to present a rare case of isolated internal iliac artery aneurysm with associated left ureteric obstruction and consequent hydronephrosis. Case report: A 66-year-old male patient was admitted for occasional pain in the lower back that appeared one month earlier. CT arteriography revealed isolated internal iliac artery (diameter 99 mm) with ureteral obstruction, hydroureter and left kidney hydronephrosis occurrence. Aneurysm was resected, after six months the patient was doing well. Bearing in mind that 77% of the patients with isolated internal iliac artery have symptoms caused by aneurysmal compression on adjacent organs, we wanted to highlight that despite the amazing expansion of endovascular procedures in the last decades, its therapeutic effect in isolated internal iliac artery's treatment is to a great extent limited since compression symptoms cannot be solved. Conclusion: Open surgery remains the gold standard for isolated internal iliac artery's treatment considering significant limitations of endovascular procedures due to the inability to eliminate problems caused by compression.
PB  - Sage Publications Ltd, London
T2  - Vascular Pharmacology
T1  - A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures
VL  - 23
IS  - 2
SP  - 170
EP  - 175
DO  - 10.1177/1708538114533963
ER  - 

@article{
author = "Nenezić, Dragoslav and Tanasković, Slobodan and Gajin, Predrag and Ilijevski, Nenad and Novaković, Aleksandra and Radak, Đorđe",
year = "2015",
abstract = "Introduction: In this report, we aim to present a rare case of isolated internal iliac artery aneurysm with associated left ureteric obstruction and consequent hydronephrosis. Case report: A 66-year-old male patient was admitted for occasional pain in the lower back that appeared one month earlier. CT arteriography revealed isolated internal iliac artery (diameter 99 mm) with ureteral obstruction, hydroureter and left kidney hydronephrosis occurrence. Aneurysm was resected, after six months the patient was doing well. Bearing in mind that 77% of the patients with isolated internal iliac artery have symptoms caused by aneurysmal compression on adjacent organs, we wanted to highlight that despite the amazing expansion of endovascular procedures in the last decades, its therapeutic effect in isolated internal iliac artery's treatment is to a great extent limited since compression symptoms cannot be solved. Conclusion: Open surgery remains the gold standard for isolated internal iliac artery's treatment considering significant limitations of endovascular procedures due to the inability to eliminate problems caused by compression.",
publisher = "Sage Publications Ltd, London",
journal = "Vascular Pharmacology",
title = "A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures",
volume = "23",
number = "2",
pages = "170-175",
doi = "10.1177/1708538114533963"
}

Nenezić, D., Tanasković, S., Gajin, P., Ilijevski, N., Novaković, A.,& Radak, Đ.. (2015). A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures. in Vascular Pharmacology
Sage Publications Ltd, London., 23(2), 170-175.
https://doi.org/10.1177/1708538114533963

Nenezić D, Tanasković S, Gajin P, Ilijevski N, Novaković A, Radak Đ. A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures. in Vascular Pharmacology. 2015;23(2):170-175.
doi:10.1177/1708538114533963 .

Nenezić, Dragoslav, Tanasković, Slobodan, Gajin, Predrag, Ilijevski, Nenad, Novaković, Aleksandra, Radak, Đorđe, "A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures" in Vascular Pharmacology, 23, no. 2 (2015):170-175,
https://doi.org/10.1177/1708538114533963 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - Guo-Wei, H.
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2072
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Cardioprotective effect of (-) epicatechin
VL  - 235
IS  - 2
SP  - e111
EP  - e111
DO  - 10.1016/j.atherosclerosis.2014.05.300
ER  - 

@conference{
author = "Novaković, Aleksandra and Vranić, Aleksandra and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and Guo-Wei, H.",
year = "2014",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Cardioprotective effect of (-) epicatechin",
volume = "235",
number = "2",
pages = "e111-e111",
doi = "10.1016/j.atherosclerosis.2014.05.300"
}

Novaković, A., Vranić, A., Janković, G., Stojanović, I., Milojević, P., Ugrešić, N., Kanjuh, V., Yang, Q.,& Guo-Wei, H.. (2014). Cardioprotective effect of (-) epicatechin. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 235(2), e111-e111.
https://doi.org/10.1016/j.atherosclerosis.2014.05.300

Novaković A, Vranić A, Janković G, Stojanović I, Milojević P, Ugrešić N, Kanjuh V, Yang Q, Guo-Wei H. Cardioprotective effect of (-) epicatechin. in Atherosclerosis. 2014;235(2):e111-e111.
doi:10.1016/j.atherosclerosis.2014.05.300 .

Novaković, Aleksandra, Vranić, Aleksandra, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, Guo-Wei, H., "Cardioprotective effect of (-) epicatechin" in Atherosclerosis, 235, no. 2 (2014):e111-e111,
https://doi.org/10.1016/j.atherosclerosis.2014.05.300 . .

TY  - JOUR
AU  - Nenezić, Dragoslav
AU  - Radak, Đorđe
AU  - Jocić, Dario
AU  - Gajin, Predrag
AU  - Tanasković, Slobodan
AU  - Novaković, Aleksandra
AU  - Matić, Predrag
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2287
AB  - Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When this occurs, several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and avoiding difficult dissection through scar tissue. Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After performed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty. Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with locally-delivered human plasmin.
AB  - Uvod Ishemija donjih ekstremiteta je posledica tromboze ili embolizacije obolele nativne arterije ili implantiranog grafta. Postoji nekoliko načina lečenja ishemije: tromboliza kateterom, mehanička trombektomija i hirurško lečenje. Osnovni razlozi za primenu perkutanih intervencija jeste izbegavanje klasičnog hirurškog lečenja kod bolesnika s visokim rizikom, kao i izbegavanje preparisanja krvnog suda u ožiljku. Prikaz bolesnika Muškarac star 67 godina primljen je u bolnicu zbog kritične ishemije donjih ekstremiteta. Po učinjenoj angiografiji dijagnostikovana je tromboza femoropoplitealnog grafta. Okluzija je rešena primenom plazmina uz upotrebu intraarterijskog katetera. Stenoze koje su otkrivene posle trombolize lečene su angioplastikom. Zaključak Trombolizom uz primenu plazmina i intraarterijskog katetera uspešno je izlečena okluzija femoropoplitealnog grafta.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin
T1  - Tromboliza okludiranog femoropoplitealnog grafta lokalno primenjenim humanim plazminom
VL  - 142
IS  - 5-6
SP  - 342
EP  - 346
DO  - 10.2298/SARH1406342N
ER  - 

@article{
author = "Nenezić, Dragoslav and Radak, Đorđe and Jocić, Dario and Gajin, Predrag and Tanasković, Slobodan and Novaković, Aleksandra and Matić, Predrag",
year = "2014",
abstract = "Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When this occurs, several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and avoiding difficult dissection through scar tissue. Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After performed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty. Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with locally-delivered human plasmin., Uvod Ishemija donjih ekstremiteta je posledica tromboze ili embolizacije obolele nativne arterije ili implantiranog grafta. Postoji nekoliko načina lečenja ishemije: tromboliza kateterom, mehanička trombektomija i hirurško lečenje. Osnovni razlozi za primenu perkutanih intervencija jeste izbegavanje klasičnog hirurškog lečenja kod bolesnika s visokim rizikom, kao i izbegavanje preparisanja krvnog suda u ožiljku. Prikaz bolesnika Muškarac star 67 godina primljen je u bolnicu zbog kritične ishemije donjih ekstremiteta. Po učinjenoj angiografiji dijagnostikovana je tromboza femoropoplitealnog grafta. Okluzija je rešena primenom plazmina uz upotrebu intraarterijskog katetera. Stenoze koje su otkrivene posle trombolize lečene su angioplastikom. Zaključak Trombolizom uz primenu plazmina i intraarterijskog katetera uspešno je izlečena okluzija femoropoplitealnog grafta.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin, Tromboliza okludiranog femoropoplitealnog grafta lokalno primenjenim humanim plazminom",
volume = "142",
number = "5-6",
pages = "342-346",
doi = "10.2298/SARH1406342N"
}

Nenezić, D., Radak, Đ., Jocić, D., Gajin, P., Tanasković, S., Novaković, A.,& Matić, P.. (2014). Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 142(5-6), 342-346.
https://doi.org/10.2298/SARH1406342N

Nenezić D, Radak Đ, Jocić D, Gajin P, Tanasković S, Novaković A, Matić P. Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin. in Srpski arhiv za celokupno lekarstvo. 2014;142(5-6):342-346.
doi:10.2298/SARH1406342N .

Nenezić, Dragoslav, Radak, Đorđe, Jocić, Dario, Gajin, Predrag, Tanasković, Slobodan, Novaković, Aleksandra, Matić, Predrag, "Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin" in Srpski arhiv za celokupno lekarstvo, 142, no. 5-6 (2014):342-346,
https://doi.org/10.2298/SARH1406342N . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Divac, Tatjana
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2042
AB  - After an acute coronary syndrome, patients remain at risk of recurrent ischemic events despite the use of antiplatelet therapy. In order to reduce the risk of recurrent ischemia in the treatment of patients with acute coronary syndromes, standard oral anticoagulants, such as vitamin K antagonists, have been introduced. These drugs have an important role in preventing stroke and systemic embolism in patients with atrial fibrillation. Vitamin K antagonists (e.g., warfarin) reduce the risk of recurrent cardio­vascular events and stroke but increase the risk of bleeding. In addition, the traditional anticoagulants have other significant drawbacks. Therefore, modulation of the coagulation process represents an important target in the development of new oral anticoagulants today. The new oral anticoagulants selectively target thrombin (dabigatran etexilate) or factor Xa (rivaroxaban, apixaban, edoxaban). Unlike traditional anticoagulants, these drugs have rapid onset of action and a relatively wide therapeutic range, do not require routine prothrombin time (PT) monitoring and have low potential for food and drug interaction. Dabigatran etexilate and rivaroxaban have been already approved in many countries for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The third phase of clinical studies in which rivaroxaban was investigated in patients with acute coronary syndrome has been successfully completed. .
AB  - Nakon akutnog koronarnog sindroma, kod bolesnika postoji povećan rizik od rekurentnih ishemičnih događaja, uprkos primeni antiagregacione terapije. U cilju smanjenja rizika od rekurentne ishemije, u terapiju visokorizičnih bolesnika sa akutnim koronarnim sindromom uvode se standardni oralni antikoagulansi, kao što su antagonisti vitamina K. Ovi lekovi imaju važnu ulogu u prevenciji moždanog udara i sistemskog embolizma kod bolesnika sa atrijalnom fibrilacijom. Antagonisti vitamina K (varfarin) smanjuju rizik od nastanka ponovnih kardiovaskularnih događaja i moždanog udara, ali povećavaju rizik od krvarenja. Pored toga, antagonisti vitamina K poseduju i druge, značajne nedostatke, tako da modulacija procesa koagulacije danas predstavlja značajnu metu za razvoj novih oralnih antikoagulanasa. Novi oralni antikoagulansi deluju selektivno na trombin (dabigatran eteksilat) ili na faktor koagulacije Xa (rivaroksaban, apiksaban, edoksaban). Za razliku od standardnih antikoagulanasa, imaju brz početak dejstva i relativno veliku terapijsku širinu, ne zahtevaju laboratorijsku kontrolu protrombinskog vremena (PT) i retko stupaju u interakcije sa hranom i lekovima. Dabigatran eteksilat i rivaroksaban su već registrovani u mnogim zemljama za prevenciju moždanog udara i sistemskog embolizma kod bolesnika sa atrijalnom fibrilacijom. Treća faza kliničke studije u okviru koje je ispitivan rivaroksaban kod bolesnika sa akutnim koronarnim sindromom uspešno je završena. .
PB  - Univerzitet u Nišu - Medicinski fakultet, Niš
T2  - Acta medica Medianae
T1  - New oral anticoagulant drugs in atrial fibrillation and acute coronary syndrome
T1  - Novi oralni antikoagulantni lekovi kod atrijalne fibrilacije i akutnog koronarnog sindroma
VL  - 52
IS  - 3
SP  - 42
EP  - 48
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2042
ER  - 

@article{
author = "Novaković, Aleksandra and Divac, Tatjana and Stojanović, Ivan and Milojević, Predrag and Nenezić, Dragoslav",
year = "2013",
abstract = "After an acute coronary syndrome, patients remain at risk of recurrent ischemic events despite the use of antiplatelet therapy. In order to reduce the risk of recurrent ischemia in the treatment of patients with acute coronary syndromes, standard oral anticoagulants, such as vitamin K antagonists, have been introduced. These drugs have an important role in preventing stroke and systemic embolism in patients with atrial fibrillation. Vitamin K antagonists (e.g., warfarin) reduce the risk of recurrent cardio­vascular events and stroke but increase the risk of bleeding. In addition, the traditional anticoagulants have other significant drawbacks. Therefore, modulation of the coagulation process represents an important target in the development of new oral anticoagulants today. The new oral anticoagulants selectively target thrombin (dabigatran etexilate) or factor Xa (rivaroxaban, apixaban, edoxaban). Unlike traditional anticoagulants, these drugs have rapid onset of action and a relatively wide therapeutic range, do not require routine prothrombin time (PT) monitoring and have low potential for food and drug interaction. Dabigatran etexilate and rivaroxaban have been already approved in many countries for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The third phase of clinical studies in which rivaroxaban was investigated in patients with acute coronary syndrome has been successfully completed. ., Nakon akutnog koronarnog sindroma, kod bolesnika postoji povećan rizik od rekurentnih ishemičnih događaja, uprkos primeni antiagregacione terapije. U cilju smanjenja rizika od rekurentne ishemije, u terapiju visokorizičnih bolesnika sa akutnim koronarnim sindromom uvode se standardni oralni antikoagulansi, kao što su antagonisti vitamina K. Ovi lekovi imaju važnu ulogu u prevenciji moždanog udara i sistemskog embolizma kod bolesnika sa atrijalnom fibrilacijom. Antagonisti vitamina K (varfarin) smanjuju rizik od nastanka ponovnih kardiovaskularnih događaja i moždanog udara, ali povećavaju rizik od krvarenja. Pored toga, antagonisti vitamina K poseduju i druge, značajne nedostatke, tako da modulacija procesa koagulacije danas predstavlja značajnu metu za razvoj novih oralnih antikoagulanasa. Novi oralni antikoagulansi deluju selektivno na trombin (dabigatran eteksilat) ili na faktor koagulacije Xa (rivaroksaban, apiksaban, edoksaban). Za razliku od standardnih antikoagulanasa, imaju brz početak dejstva i relativno veliku terapijsku širinu, ne zahtevaju laboratorijsku kontrolu protrombinskog vremena (PT) i retko stupaju u interakcije sa hranom i lekovima. Dabigatran eteksilat i rivaroksaban su već registrovani u mnogim zemljama za prevenciju moždanog udara i sistemskog embolizma kod bolesnika sa atrijalnom fibrilacijom. Treća faza kliničke studije u okviru koje je ispitivan rivaroksaban kod bolesnika sa akutnim koronarnim sindromom uspešno je završena. .",
publisher = "Univerzitet u Nišu - Medicinski fakultet, Niš",
journal = "Acta medica Medianae",
title = "New oral anticoagulant drugs in atrial fibrillation and acute coronary syndrome, Novi oralni antikoagulantni lekovi kod atrijalne fibrilacije i akutnog koronarnog sindroma",
volume = "52",
number = "3",
pages = "42-48",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2042"
}

Novaković, A., Divac, T., Stojanović, I., Milojević, P.,& Nenezić, D.. (2013). New oral anticoagulant drugs in atrial fibrillation and acute coronary syndrome. in Acta medica Medianae
Univerzitet u Nišu - Medicinski fakultet, Niš., 52(3), 42-48.
https://hdl.handle.net/21.15107/rcub_farfar_2042

Novaković A, Divac T, Stojanović I, Milojević P, Nenezić D. New oral anticoagulant drugs in atrial fibrillation and acute coronary syndrome. in Acta medica Medianae. 2013;52(3):42-48.
https://hdl.handle.net/21.15107/rcub_farfar_2042 .

Novaković, Aleksandra, Divac, Tatjana, Stojanović, Ivan, Milojević, Predrag, Nenezić, Dragoslav, "New oral anticoagulant drugs in atrial fibrillation and acute coronary syndrome" in Acta medica Medianae, 52, no. 3 (2013):42-48,
https://hdl.handle.net/21.15107/rcub_farfar_2042 .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Milojević, Predrag
AU  - Babić, Milan
AU  - Stojanović, Ivan
AU  - Jović, Miomir
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1728
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Circulation
T1  - Relaxation of arterial graft induced by nicorandil
VL  - 125
IS  - 19
SP  - e184
EP  - e184
DO  - 10.1161/CIR.0b013e31824fcdb3
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1728
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Milojević, Predrag and Babić, Milan and Stojanović, Ivan and Jović, Miomir and Nenezić, Dragoslav and Ugrešić, Nenad and Yang, Qin and He, Guo-Wei",
year = "2012",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Circulation",
title = "Relaxation of arterial graft induced by nicorandil",
volume = "125",
number = "19",
pages = "e184-e184",
doi = "10.1161/CIR.0b013e31824fcdb3",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1728"
}

Novaković, A., Marinko, M., Milojević, P., Babić, M., Stojanović, I., Jović, M., Nenezić, D., Ugrešić, N., Yang, Q.,& He, G.. (2012). Relaxation of arterial graft induced by nicorandil. in Circulation
Lippincott Williams & Wilkins, Philadelphia., 125(19), e184-e184.
https://doi.org/10.1161/CIR.0b013e31824fcdb3
https://hdl.handle.net/21.15107/rcub_farfar_1728

Novaković A, Marinko M, Milojević P, Babić M, Stojanović I, Jović M, Nenezić D, Ugrešić N, Yang Q, He G. Relaxation of arterial graft induced by nicorandil. in Circulation. 2012;125(19):e184-e184.
doi:10.1161/CIR.0b013e31824fcdb3
https://hdl.handle.net/21.15107/rcub_farfar_1728 .

Novaković, Aleksandra, Marinko, Marija, Milojević, Predrag, Babić, Milan, Stojanović, Ivan, Jović, Miomir, Nenezić, Dragoslav, Ugrešić, Nenad, Yang, Qin, He, Guo-Wei, "Relaxation of arterial graft induced by nicorandil" in Circulation, 125, no. 19 (2012):e184-e184,
https://doi.org/10.1161/CIR.0b013e31824fcdb3 .,
https://hdl.handle.net/21.15107/rcub_farfar_1728 .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Pavlović, M.
AU  - Vranić, Aleksandra
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Jović, M.
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1702
PB  - Oxford Univ Press, Oxford
C3  - Cardiovascular Research
T1  - Different potassium channels are involved in relaxation of arterial graft induced by nicorandil
VL  - 93
DO  - 10.1093/cvr/cvr332
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1702
ER  - 

@conference{
author = "Novaković, Aleksandra and Pavlović, M. and Vranić, Aleksandra and Milojević, Predrag and Stojanović, Ivan and Jović, M. and Nenezić, Dragoslav and Ugrešić, Nenad and Yang, Qin and He, Guo-Wei",
year = "2012",
publisher = "Oxford Univ Press, Oxford",
journal = "Cardiovascular Research",
title = "Different potassium channels are involved in relaxation of arterial graft induced by nicorandil",
volume = "93",
doi = "10.1093/cvr/cvr332",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1702"
}

Novaković, A., Pavlović, M., Vranić, A., Milojević, P., Stojanović, I., Jović, M., Nenezić, D., Ugrešić, N., Yang, Q.,& He, G.. (2012). Different potassium channels are involved in relaxation of arterial graft induced by nicorandil. in Cardiovascular Research
Oxford Univ Press, Oxford., 93.
https://doi.org/10.1093/cvr/cvr332
https://hdl.handle.net/21.15107/rcub_farfar_1702

Novaković A, Pavlović M, Vranić A, Milojević P, Stojanović I, Jović M, Nenezić D, Ugrešić N, Yang Q, He G. Different potassium channels are involved in relaxation of arterial graft induced by nicorandil. in Cardiovascular Research. 2012;93.
doi:10.1093/cvr/cvr332
https://hdl.handle.net/21.15107/rcub_farfar_1702 .

Novaković, Aleksandra, Pavlović, M., Vranić, Aleksandra, Milojević, Predrag, Stojanović, Ivan, Jović, M., Nenezić, Dragoslav, Ugrešić, Nenad, Yang, Qin, He, Guo-Wei, "Different potassium channels are involved in relaxation of arterial graft induced by nicorandil" in Cardiovascular Research, 93 (2012),
https://doi.org/10.1093/cvr/cvr332 .,
https://hdl.handle.net/21.15107/rcub_farfar_1702 .